A Phase 3 interventional study of Belimumab and Rituximab in Systemic Lupus Erythematosus, sponsored by GlaxoSmithKline. Completed at 79 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-18.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing rituximab in Lupus Erythematosus, Systemic — 2 open to participants now, 2 under way, none of them phase 3. Rituximab · Lupus Erythematosus, Systemic.
Among the 14 studies testing rituximab in Lupus Erythematosus, Systemic, this one has the largest enrollment, is the only one that started in 2018, is one of 4 in phase 3, and was the 11th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →2 of the 14 studies testing rituximab in Lupus Erythematosus, Systemic are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–65
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 5 · Phase 4 1
First in 2001; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 292 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 27 across the 14 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 14 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline: 1 open now, 4 under way, none of them phase 3. Of 36 finished, 26 (72%) have results posted.
Among the 43 studies in Lupus Erythematosus, Systemic by GlaxoSmithKline, this one is the 12th largest by enrollment of the 36 interventional ones that give a count, is one of 2 that started in 2018, is one of 10 in phase 3, and was the 32nd registered.
GlaxoSmithKline’s Lupus Erythematosus, Systemic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing rituximab in Lupus Erythematosus, Systemic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 43 in Lupus Erythematosus, Systemic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess whether co-administration of belimumab and a single cycle of rituximab will optimize treatment with belimumab, which will result in improvements of clinical status with a favorable safety profile, by comparing subjects randomized to belimumab plus rituximab versus belimumab plus rituximab-placebo. Approximately 292 subjects will be randomized in a 1:2:1 ratio to 1 of 3 treatment arms; belimumab plus rituximab-placebo (Arm A, control), belimumab plus rituximab (Arm B, combination), or belimumab plus standard therapy (Arm C, reference). Belimumab will be administered as subcutaneous (SC) and rituximab-placebo or rituximab will be administered by intravenous (IV) infusions. The total duration of the study is for 104 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible subjects will receive Belimumab 200 milligrams (mg) to be administered subcutaneously (SC) on Day 1 and then weekly (i.e., every 7 days) through Week 52. Subjects will also receive rituximab-placebo to be administered by intravenous (IV) infusions at Weeks 4 and 6 in double blind manner. Subjects will receive standard therapy excluding Immunosuppressants and including anti-malarials, non-steroidal anti-inflammatory drugs (NSAIDs), and/or corticosteroids tapered down to prednisone equivalent of less than or equal to (\<=) 5 mg/day until Week 104. Subjects will not receive treatment after 52 weeks and will be in observation until Week 104.
Drug: Belimumab · Drug: Rituximab-placebo · Drug: Standard therapy (Excluding Immunosuppressants) · Drug: Steroid Taper
Eligible subjects will receive Belimumab 200 mg to be administered SC on Day 1 and then weekly (i.e., every 7 days) through Week 52. Subjects will also receive rituximab 1000 mg to be administered by IV infusions at Weeks 4 and 6 in double blind manner. Subjects will receive standard therapy excluding Immunosuppressants and including anti-malarials, NSAIDs, and/or corticosteroids tapered down to prednisone equivalent of \<= 5 mg/day until Week 104. Subjects will not receive treatment after 52 weeks and will be in observation until Week 104.
Drug: Belimumab · Drug: Rituximab · Drug: Standard therapy (Excluding Immunosuppressants) · Drug: Steroid Taper
Eligible subjects will receive open-label Belimumab 200 mg administered SC on Day 1 and then weekly (i.e., every 7 days) until Week 104. Subjects will also receive standard therapy including immunosuppressant, anti-malarials, NSAIDs, and/or corticosteroids tapered down to prednisone equivalent of \<= 5 mg/day until Week 104.
Drug: Belimumab · Drug: Standard therapy (Including Immunosuppressants) · Drug: Steroid Taper
Belimumab will be administered as SC injection once weekly via autoinjector in thigh or abdomen
Rituximab will be administered as IV infusion of 1000mg at Week 4 and Week 6
Saline will be administered as IV infusions at Week 4 and Week 6
Standard therapy will contain stable SLE medications including immunosuppressant to be administered from baseline through Week 104.
Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with prednisone dose equivalent to \<= 5 mg/day will administered through Week 104.
Steroid taper will include prednisone doses equivalent to =\< 5 mg/day in all Arms through Week 104.
Percentage of Participants With a State of Disease Control at Week 52
Percentage of participants with a state of disease control (Independent blinded assessor \[IBA\]) was defined as the percentage of participants with a Systemic Lupus Erythematosus Disease Activity Index 2000(SLEDAI-2K)score less than or equal to(\<=)2 achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of \<=5 mg/day at Week 52. SLEDAI-2K was a weighted, cumulative index for measuring systemic lupus erythematosus (SLE) disease activity in previous 10 days,consisting 24 individual items in which signs and symptoms, laboratory tests and physician's assessment for each item within each of 9 organ systems were given a weighted score(1 to 8 with higher score indicating increased activity)and summed if present at the time of visit or in preceding 10 days. The SLEDAI-2K score was sum of all 24 individual items from the SLEDAI-2K, ranges from 0(no symptoms) to 105(presence of all defined symptoms) with higher scores representing increased disease activity.
Time frame: Week 52
Percentage of Participants With a State of Clinical Remission at Week 64
Percentage of participants with a state of clinical remission (IBA) was defined as percentage of participants with a clinical SLEDAI-2K score =0 (does not include anti-double stranded deoxyribonucleic \[dsDNA\] and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day at Week 64. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days, consisting 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity.
Time frame: Week 64
Percentage of Participants With a State of Disease Control at Week 104
Percentage of participants with a state of disease control (IBA) was defined as the percentage of participants with a SLEDAI-2K score \<=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of \<=5 mg/day at Week 104. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days which consisted of 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity.
Time frame: Week 104
Percentage of Participants With a State of Disease Control by Visits
Percentage of participants with a state of disease control (IBA) was defined as the percentage of participants with a SLEDAI-2K score \<=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of \<=5 mg/day. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days which consisted of 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity.
Time frame: Weeks 12, 26, 40, 52, 64, 80 and 104
Percentage of Participants With a State of Clinical Remission by Visits
Percentage of participants with a state of clinical remission (IBA) was defined as percentage of participants with a clinical SLEDAI-2K score =0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days, consisting 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity
Time frame: Weeks 64, 80 and 104
Percentage of Participants With a State of Complete Remission (CR) Sustained for at Least 24 Weeks During Week 52 to Week 104
Percentage of participants with a state of CR (Principal Investigator \[PI\] assessed) was defined as percentage of participants with a SLEDAI-2K=0 achieved without immunosuppressants and with corticosteroids at prednisone equivalent dose of 0 mg/day,sustained for at least 24 weeks. Sustained CR was longest period a participant maintains CR without break calculated as last consecutive CR date minus first consecutive CR date plus 1. SLEDAI-2K consisted of 24 individual items within each 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at time of visit or in preceding 10 days. SLEDAI-2K score was sum of all 24 individual items from SLEDAI-2K, ranges from 0(no symptoms) to 105(presence of all defined symptoms),higher scores indicates increased disease activity. Percentage of participants with a state of CR sustained for at least 24 weeks at any visit during Week 52 to Week 104 were reported.
Time frame: Week 52 to Week 104
Percentage of Participants With a State of Clinical Remission (CLR) Sustained for at Least 24 Weeks From Week 80 to Week 104
Percentage of participants with a state of CLR (PI assessed) at Week 104 was defined as percentage of participants with a clinical SLEDAI-2K score=0 (does not include anti-dsDNA and complement activity scores) achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day, sustained for at least 24 weeks(from Week 80 to Week 104). Sustained CLR is longest period a participant maintains CLR without a break, calculated as last consecutive CLR date minus first consecutive CLR date plus 1. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score(1 to 8 with higher score indicating increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity.
Time frame: From Week 80 to Week 104
Percentage of Participants With a State of Complete Remission by Visits
Percentage of participants with a state of complete remission (PI assessed) was defined as the percentage of participants with a SLEDAI-2K score =0, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. SLEDAI-2K was a weighted, cumulative index for measuring systemic lupus erythematosus (SLE) disease activity in the previous 10 days which consisted of 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within for each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity.
Time frame: Weeks 60, 64, 72, 80, 88, 96 and 104
Time to First Severe Flare
Time to first severe SLE flare was the number of days from treatment start date until the participant met an event. Time to first severe flare was defined as event date minus treatment start date plus 1. Time to first severe flare was measured by Modified SLE flare index which identifies whether a participant had experienced a mild/moderate or severe flare. Analysis of first severe flare was performed on the modified SLE Flare index that excludes severe flares that were triggered only by an increase is SLEDAI-2K score to greater than 12.
Time frame: Up to Week 104
Time to First Flare
Time to first SLE flare was the number of days from treatment start date until the participant met an event. Time to first flare was defined as event date minus treatment start date plus 1. Time to first flare was measured by modified SLE flare index which identifies whether a participant had experienced a mild/moderate or severe flare.
Time frame: Up to Week 104
Time to Disease Control Sustained for at Least 24 Weeks and Maintained Through Week 104
Disease control sustained for at least 24 weeks and maintained through Week 104 was defined as SLEDAI-2K score \<=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of \<=5 mg/day. Time to disease control (PI assessed) was defined as the first visit of sustained disease control until Week 104 on or before Week 80 minus treatment start date (Day 1) plus 1. Sustained disease control was longest period a participant maintained disease control without a break. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. SLEDAI-2K score was the sum of all 24 individual items from SLEDAI-2K , ranges from 0 (no symptoms) to 105 (presence of all defined symptoms),higher scores representing increased disease activity.
Time frame: Up to Week 104
Time to Clinical Remission Sustained for at Least 24 Weeks and Maintained Through Week 104
Clinical remission sustained for at least 24 weeks and maintained through Week 104 was defined as clinical SLEDAI-2K score=0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. Time to CLR (PI assessed) was defined as first visit of sustained CLR until Week 104 on or before Week 80 minus treatment start date (Day 1) plus 1. Sustained CLR was longest period a participant maintained clinical remission without a break. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity.
Time frame: Up to Week 104
Duration of Disease Control
Duration of disease control was defined as SLEDAI-2K score \<=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of \<=5 mg/day. The duration of disease control (PI assessed) was the longest period between 2 visits that the participant was a disease control responder at all visits and calculated as the first visit of disease control minus last visit of disease control plus 1. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. SLEDAI-2K score was the sum of all 24 individual items from SLEDAI-2K, ranges from 0(no symptoms) to 105 (presence of all defined symptoms),higher scores representing increased disease activity
Time frame: Up to Week 104
Duration of Clinical Remission
Clinical remission was defined as clinical SLEDAI-2K score =0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. The duration of clinical remission (PI assessed) was the longest period between 2 visits that the participant was a clinical remission responder at all visits and was calculated as the first visit of clinical remission minus last visit of clinical remission plus 1. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity.
Time frame: Up to Week 104
Change From Baseline in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Score by Visit (PI Assessed)
The SLEDAI-2K consisted of 24 individual items within 9 organ systems. Each item was given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of visit or in the preceding 10 days. Weighted scores for central nervous system (CNS) (7 items) was 8; for vascular (1 item) was 8; for Musculoskeletal (2 items) was 4; for Renal (4 items) was 4; for Mucocutaneous (3 items) was 2; for Cardiovascular and Respiratory (2 items) was 2; for Immunologic (2 items) was 2;for Constitutional (1 item) was 1 and for Hematologic (2 items) was 1. SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. Baseline value was latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104
Percentage of Participants With SLEDAI-2K Organ Improvement Compared to Baseline by Visits (PI Assessed)
SLEDAI-2K assessments consisted of 24 individual items with 9 organ systems. Each item was given a weighted score(1 to 8 with higher score indicating increased activity)and summed if present at the time of analysis. SLEDAI-2K score was sum of all 24 individual items from SLEDAI-2K ranges from 0(no symptoms) to 105(presence of all defined symptoms). Higher scores indicates increased disease activity. An improvement was defined as a decrease(compared to Baseline) in SLEDAI-2K score within same organ system at a post-Baseline visit. Baseline value was latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Data for following organ systems was reported: CNS total, Vascular total, Musculoskeletal total, Renal total, Mucocutaneous total, Cardiovascular (Cardio) and Respiratory (Resp) total, Immunologic total and Hematologic total. Constitutional organ system was removed from analysis and its one item (fever)moved to hematologic organ system.
Time frame: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104
Percentage of Participants With SLEDAI-2K Organ Worsening Compared to Baseline by Visits (PI Assessed)
SLEDAI-2K assessments consisted of 24 individual items with 9 organ systems. Each item was given a weighted score(1 to 8 with higher score indicating increased activity)and summed if present at time of analysis. SLEDAI-2K score was sum of all 24 individual items from SLEDAI-2K, ranges from 0(no symptoms) to 105(presence of all defined symptoms). Higher scores indicates increased disease activity. A worsening was defined as an increase(compared to Baseline) in SLEDAI-2K score within same organ system at a post-Baseline visit. Baseline value was latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Percentage of participants with SLEDAI-2K organ worsening for following organ systems were reported;CNS total,Vascular total,Musculoskeletal total,Renal total,Mucocutaneous total,Cardio and Resp total,Immunologic total and Hematologic total. Constitutional organ system was removed from analysis and its one item (fever)moved to hematologic organ system.
Time frame: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104
Change From Baseline in Physician Global Assessment (PGA) by Visits
The Physician's Global Assessment (PGA) was a physician-reported visual analogue scale that provides an overall measure of the participant's current disease activity. Physician's Global Assessment was collected on a 10 centimeter (cm) visual analogue scale (VAS) by placing a mark on the scale between 0 (no disease activity) to 10 (maximum disease activity). The PGA score was then rescaled for reporting by multiplying the collected score by 3 divided by 10. Hence, the PGA score ranges from 0 to 3 with higher scores indicating greater disease activity. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as the post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104
Percentage of Participants With Systemic Lupus International Collaborating Clinics (SLICC) -American College of Rheumatology (ACR) Damage Index Worsening Compared With Baseline at Week 52 and Week 104
The SLICC-ACR Damage Index measures irreversible (not related to active inflammation) changes occurring since the diagnosis of SLE ascertained by clinical assessment and present for at least 6 months. The questionnaire contains 39 items covering 12 different organ systems which were scored on a numerical scale between 0 (no damage) to 7 (increasing disease damage). Individual ranges for organ systems were; ocular: 0-2, neuropsychiatric: 0-6, renal: 0-3, pulmonary: 0-5, cardiovascular:0-6, peripheral vascular: 0-5, gastrointestinal:0-5, musculoskeletal: 0-6, skin: 0-3, endocrine (diabetes): 0-1, gonadal:0-1 and malignancies: 0-2. The SLICC-ACR score was calculated by taking sum of the individual scores for 12 organ systems which ranges from 0 (no damage) to 45 (increasing disease damage) where higher score indicates increasing disease damage severity. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
Time frame: Baseline (Day 1), Week 52 and Week 104
Percentage of Participants That Met the Lupus Low Disease Activity State (LLDAS) Response Criteria by Visits (PI Assessed)
Lupus low disease activity state (LLDAS) was defined as a state which, if sustained, was associated with a low likelihood of adverse outcome, considering disease activity and medication safety. The LLDAS response criteria were: (1) SLEDAI-2K \<=4, with no activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis, fever) and no hemolytic anemia or gastrointestinal activity; (2) no new features of lupus disease activity compared with the previous assessment; (3) PGA (scale 0-3), \<=1; (4) current prednisolone (or equivalent) dose \<=7.5 mg daily; and (5) well tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs. Percentage of participants that met the LLDAS response criteria were reported.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96 and 104
Percentage of Participants With a State of Disease Control Using the PI Assessment of SLEDAI-2K by Visit
Percentage of participants with a state of disease control was defined as the percentage of participants with a SLEDAI-2K score \<=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of \<=5 mg/day, using the PI assessment of SLEDAI-2K. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. SLEDAI-2K score was the sum of all 24 individual items from SLEDAI-2K, ranges from 0 (no symptoms) to 105 (presence of all defined symptoms), higher scores representing increased disease activity. Percentage of participants with a state of disease control using the PI assessment of SLEDAI-2K were summarized.
Time frame: Weeks 4, 8, 12, 16, 20, 24, 26, 28, 32, 36, 40, 44, 48, 52, 60, 64, 72, 80, 88, 96, 104
Percentage of Participants With a State of Clinical Remission Using the PI Assessment of SLEDAI-2K by Visit
Percentage of participants with a state of clinical remission was defined as the percentage of participants with a clinical SLEDAI-2K score =0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants (which was allowed in Belimumab+ Standard therapy arm only) and with corticosteroids at a prednisone equivalent dose of 0 mg/day using the PI assessment of SLEDAI-2K. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity. Percentage of participants with a state of clinical remission using the PI assessment of SLEDAI-2K were summarized.
Time frame: Weeks 60, 64, 72, 80, 88, 96 and 104
Number of Participants With Serious Adverse Events (SAE) and Non-serious AE (Non-SAE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situations as per medical or scientific judgment. Data for number of participants with SAE and non-SAE (\>=5 %) has been summarized.
Time frame: Up to Week 111 (including 8 weeks of safety follow-up)
Number of Participants With Adverse Events of Special Interest (AESIs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AESIs were Malignant Neoplasms, Post-Injection Systemic Reactions (PISR), All Infections of Special Interest (Opportunistic Infections (OI), Herpes Zoster (HZ), Tuberculosis (TB), and Sepsis), Depression (including mood disorders and anxiety)/suicide/self-injury and Deaths. Data for number of participants with AESIs has been summarized.
Time frame: Up to Week 104
Change From Baseline in Patient Global Assessment (PtGA) by Visits
The Patient's Global Assessment (PtGA) of Disease Activity is a single-item, participant reported scale developed for the assessment of the participant's overall rating of their disease activity due to SLE. The scale measures disease activity ranging from 0 (Very Well) to 10 (Very Poor) and the higher score indicates severe disease activity. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as the post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and Weeks 8, 12, 26, 40, 52, 64, 72 and 104
Change From Baseline in Lupus Quality of Life (LupusQoL) Domain Scores by Visit
LupusQoL is a SLE-specific health related qualify of life (HRQOL) instrument with 34 questions across 8 domains:Physical health(8 items),Pain(3 items),Planning(3 items),Intimate relationship(2 items),Burden to others(3 items),Emotional health(6 items),Body image(5 items),Fatigue(4 items). Questions were related to participants experience in prior 4 weeks.A 5-point Likert response format was used, ranging from 0(all of the time) to 4(never) for each question. Individual domain scores were reported which were calculated by taking sum of responses to all items within each domain. Individual domain scores range:Physical health(0-32),Pain(0-12),Planning(0-12),Intimate relationship(0-8),Burden to others(0-12),Emotional health(0-24),Body image(0-20),Fatigue(0-16). Higher score indicates better HRQOL. Baseline value was latest pre-dose assessment with a non-missing value including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and Weeks 8, 12, 26, 40, 52, 64, 72 and 104
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score by Visit
The FACIT-Fatigue scale was a 13-item questionnaire completed by the participant, which provides a measure of fatigue/quality of life, with a 7-day recall period. The participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The higher score for the questions, the greater the fatigue. The total score was the sum of the responses from all questions (inverted for reversed items) multiplied by 13, then divided by the number of questions answered, ranging from 0 (worse fatigue) to 52 (no fatigue) where a higher score indicates an improvement in the participant's health status and decrease in the score indicates worse fatigue/quality of life. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as the post-dose visit value minus Baseline value.
Time frame: Baseline (Day 1) and Weeks 8, 12, 26, 40, 52, 64, 72 and 104
Percentage of Participants With Improvement in FACIT-Fatigue Score Exceeding the Minimal Clinically Important Difference (MCID, Greater Than or Equal to [>=]4)
The FACIT-Fatigue scale was a 13-item questionnaire completed by the participant, which provides a measure of fatigue/quality of life, with a 7-day recall period. The participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions, the greater the fatigue. The total score was the sum of the responses (inverted for reversed items) multiplied by 13, then divided by the number of questions answered, ranging from 0 (worse fatigue) to 52 (no fatigue) where a higher score indicates an improvement in the participant's health status and decrease in the score indicates worse fatigue/quality of life. A participant was considered to had an improvement exceeding the minimal clinically important difference if they had \>=4 points improvement in their FACIT-Fatigue Scale score from Baseline. Percentage of participants with improvement in FACIT-Fatigue scale score exceeding the MCID (\>=4 points) were summarized.
Time frame: Weeks 8, 12, 26, 40, 52, 64, 72 and 104
This was a multicenter study conducted at 71 centers in 11 countries. This was a randomized, placebo-controlled, parallel study where participants received treatment in any one of the treatment arms.
| Milestone | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Started | 72 | 144 | 76 |
| Completed | 55 | 114 | 57 |
| Not completed | 17 | 30 | 19 |
| Withdrew: Adverse event | 1 | 6 | 1 |
| Withdrew: Protocol violation | 2 | 3 | 4 |
| Withdrew: Lost to follow-up | 2 | 3 | 2 |
| Withdrew: Physician decision | 3 | 4 | 2 |
| Withdrew: Withdrawal by subject | 9 | 14 | 10 |
Percentage of participants with a state of disease control (Independent blinded assessor \[IBA\]) was defined as the percentage of participants with a Systemic Lupus Erythematosus Disease Activity Index 2000(SLEDAI-2K)score less than or equal to(\<=)2 achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of \<=5 mg/day at Week 52. SLEDAI-2K was a weighted, cumulative index for measuring systemic lupus erythematosus (SLE) disease activity in previous 10 days,consisting 24 individual items in which signs and symptoms, laboratory tests and physician's assessment for each item within each of 9 organ systems were given a weighted score(1 to 8 with higher score indicating increased activity)and summed if present at the time of visit or in preceding 10 days. The SLEDAI-2K score was sum of all 24 individual items from the SLEDAI-2K, ranges from 0(no symptoms) to 105(presence of all defined symptoms) with higher scores representing increased disease activity.
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Percentage of Participants With a State of Disease Control at Week 52 | 16.7 (8.1 to 25.3) | 19.4 (13.0 to 25.9) | 25.5 (13.1 to 38.0) |
Percentage of participants with a state of clinical remission (IBA) was defined as percentage of participants with a clinical SLEDAI-2K score =0 (does not include anti-double stranded deoxyribonucleic \[dsDNA\] and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day at Week 64. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days, consisting 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity.
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Percentage of Participants With a State of Clinical Remission at Week 64 | 5.6 (0.3 to 10.8) | 6.3 (2.3 to 10.2) | 10.6 (1.8 to 19.5) |
Percentage of participants with a state of disease control (IBA) was defined as the percentage of participants with a SLEDAI-2K score \<=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of \<=5 mg/day at Week 104. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days which consisted of 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity.
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Percentage of Participants With a State of Disease Control at Week 104 | 6.9 (1.1 to 12.8) | 11.1 (6.0 to 16.2) | 21.3 (9.6 to 33.0) |
Percentage of participants with a state of disease control (IBA) was defined as the percentage of participants with a SLEDAI-2K score \<=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of \<=5 mg/day. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days which consisted of 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity.
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Week 12 | 8.3 (1.9 to 14.7) | 12.5 (7.1 to 17.9) | 21.3 (9.6 to 33.0) |
| Week 26 | 16.7 (8.1 to 25.3) | 21.5 (14.8 to 28.2) | 25.5 (13.1 to 38.0) |
| Week 40 | 13.9 (5.9 to 21.9) | 20.8 (14.2 to 27.5) | 23.4 (11.3 to 35.5) |
| Week 52 | 16.7 (8.1 to 25.3) | 19.4 (13.0 to 25.9) | 25.5 (13.1 to 38.0) |
| Week 64 | 11.1 (3.9 to 18.4) | 18.1 (11.8 to 24.3) | 25.5 (13.1 to 38.0) |
| Week 80 | 6.9 (1.1 to 12.8) | 13.2 (7.7 to 18.7) | 27.7 (14.9 to 40.4) |
| Week 104 | 6.9 (1.1 to 12.8) | 11.1 (6.0 to 16.2) | 21.3 (9.6 to 33.0) |
Percentage of participants with a state of clinical remission (IBA) was defined as percentage of participants with a clinical SLEDAI-2K score =0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. SLEDAI-2K was a weighted, cumulative index for measuring SLE disease activity in previous 10 days, consisting 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Week 64 | 5.6 (0.3 to 10.8) | 6.3 (2.3 to 10.2) | 10.6 (1.8 to 19.5) |
| Week 80 | 4.2 (0 to 8.8) | 4.2 (0.9 to 7.4) | 12.8 (3.2 to 22.3) |
| Week 104 | 1.4 (0 to 4.1) | 4.2 (0.9 to 7.4) | 6.4 (0 to 13.4) |
Percentage of participants with a state of CR (Principal Investigator \[PI\] assessed) was defined as percentage of participants with a SLEDAI-2K=0 achieved without immunosuppressants and with corticosteroids at prednisone equivalent dose of 0 mg/day,sustained for at least 24 weeks. Sustained CR was longest period a participant maintains CR without break calculated as last consecutive CR date minus first consecutive CR date plus 1. SLEDAI-2K consisted of 24 individual items within each 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at time of visit or in preceding 10 days. SLEDAI-2K score was sum of all 24 individual items from SLEDAI-2K, ranges from 0(no symptoms) to 105(presence of all defined symptoms),higher scores indicates increased disease activity. Percentage of participants with a state of CR sustained for at least 24 weeks at any visit during Week 52 to Week 104 were reported.
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Percentage of Participants With a State of Complete Remission (CR) Sustained for at Least 24 Weeks During Week 52 to Week 104 | 2.8 (0 to 6.6) | 0 (NA to NA) | 6.4 (0 to 13.4) |
Percentage of participants with a state of CLR (PI assessed) at Week 104 was defined as percentage of participants with a clinical SLEDAI-2K score=0 (does not include anti-dsDNA and complement activity scores) achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day, sustained for at least 24 weeks(from Week 80 to Week 104). Sustained CLR is longest period a participant maintains CLR without a break, calculated as last consecutive CLR date minus first consecutive CLR date plus 1. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score(1 to 8 with higher score indicating increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity.
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Percentage of Participants With a State of Clinical Remission (CLR) Sustained for at Least 24 Weeks From Week 80 to Week 104 | 2.8 (0 to 6.6) | 2.1 (0 to 4.4) | 4.3 (0 to 10.0) |
Percentage of participants with a state of complete remission (PI assessed) was defined as the percentage of participants with a SLEDAI-2K score =0, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. SLEDAI-2K was a weighted, cumulative index for measuring systemic lupus erythematosus (SLE) disease activity in the previous 10 days which consisted of 24 individual items in which signs and symptoms, laboratory tests, and physician's assessment for each item within for each of 9 organ systems were given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of the visit or in the preceding 10 days. The SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity.
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Week 60 | 5.6 (0.3 to 10.8) | 0.7 (0 to 2.1) | 6.4 (0 to 13.4) |
| Week 64 | 5.6 (0.3 to 10.8) | 0.7 (0 to 2.1) | 6.4 (0 to 13.4) |
| Week 72 | 4.2 (0 to 8.8) | 0.7 (0 to 2.1) | 6.4 (0 to 13.4) |
| Week 80 | 2.8 (0 to 6.6) | 1.4 (0 to 3.3) | 8.5 (0.5 to 16.5) |
| Week 88 | 2.8 (0 to 6.6) | 0 (NA to NA) | 4.3 (0 to 10.0) |
| Week 96 | 1.4 (0 to 4.1) | 0.7 (0 to 2.1) | 6.4 (0 to 13.4) |
| Week 104 | 1.4 (0 to 4.1) | 0.7 (0 to 2.1) | 4.3 (0 to 10.0) |
Time to first severe SLE flare was the number of days from treatment start date until the participant met an event. Time to first severe flare was defined as event date minus treatment start date plus 1. Time to first severe flare was measured by Modified SLE flare index which identifies whether a participant had experienced a mild/moderate or severe flare. Analysis of first severe flare was performed on the modified SLE Flare index that excludes severe flares that were triggered only by an increase is SLEDAI-2K score to greater than 12.
| Days | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Time to First Severe Flare | 372.0 (202.0 to 485.0) | 379.0 (198.0 to NA) | 730.0 (210.0 to NA) |
Time to first SLE flare was the number of days from treatment start date until the participant met an event. Time to first flare was defined as event date minus treatment start date plus 1. Time to first flare was measured by modified SLE flare index which identifies whether a participant had experienced a mild/moderate or severe flare.
| Days | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Time to First Flare | 168.0 (92.0 to 257.0) | 170.0 (57.0 to 365.0) | 168.0 (91.0 to 337.0) |
Disease control sustained for at least 24 weeks and maintained through Week 104 was defined as SLEDAI-2K score \<=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of \<=5 mg/day. Time to disease control (PI assessed) was defined as the first visit of sustained disease control until Week 104 on or before Week 80 minus treatment start date (Day 1) plus 1. Sustained disease control was longest period a participant maintained disease control without a break. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. SLEDAI-2K score was the sum of all 24 individual items from SLEDAI-2K , ranges from 0 (no symptoms) to 105 (presence of all defined symptoms),higher scores representing increased disease activity.
| Days | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Time to Disease Control Sustained for at Least 24 Weeks and Maintained Through Week 104 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Clinical remission sustained for at least 24 weeks and maintained through Week 104 was defined as clinical SLEDAI-2K score=0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. Time to CLR (PI assessed) was defined as first visit of sustained CLR until Week 104 on or before Week 80 minus treatment start date (Day 1) plus 1. Sustained CLR was longest period a participant maintained clinical remission without a break. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity.
| Days | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Time to Clinical Remission Sustained for at Least 24 Weeks and Maintained Through Week 104 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Duration of disease control was defined as SLEDAI-2K score \<=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of \<=5 mg/day. The duration of disease control (PI assessed) was the longest period between 2 visits that the participant was a disease control responder at all visits and calculated as the first visit of disease control minus last visit of disease control plus 1. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. SLEDAI-2K score was the sum of all 24 individual items from SLEDAI-2K, ranges from 0(no symptoms) to 105 (presence of all defined symptoms),higher scores representing increased disease activity
| Days | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Duration of Disease Control | 49.5 (1.0 to 172.0) | 116.0 (21.0 to 265.0) | 116.0 (23.0 to 351.0) |
Clinical remission was defined as clinical SLEDAI-2K score =0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of 0 mg/day. The duration of clinical remission (PI assessed) was the longest period between 2 visits that the participant was a clinical remission responder at all visits and was calculated as the first visit of clinical remission minus last visit of clinical remission plus 1. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity.
| Days | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Duration of Clinical Remission | 31.0 (1.0 to 253.0) | 73.0 (29.0 to 225.0) | 176.0 (85.0 to 279.0) |
The SLEDAI-2K consisted of 24 individual items within 9 organ systems. Each item was given a weighted score (1 to 8 with higher score indicating increased activity) and summed if present at the time of visit or in the preceding 10 days. Weighted scores for central nervous system (CNS) (7 items) was 8; for vascular (1 item) was 8; for Musculoskeletal (2 items) was 4; for Renal (4 items) was 4; for Mucocutaneous (3 items) was 2; for Cardiovascular and Respiratory (2 items) was 2; for Immunologic (2 items) was 2;for Constitutional (1 item) was 1 and for Hematologic (2 items) was 1. SLEDAI-2K score was the sum of all 24 individual items from the SLEDAI-2K which ranges from 0 (no symptoms) to 105 (presence of all defined symptoms) with higher scores representing increased disease activity. Baseline value was latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Scores on a scale | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Week 4; n=69, 137, 43 | -1.4 ± 2.75 | -0.8 ± 3.39 | -1.3 ± 3.15 |
| Week 8; n=63, 132, 43 | -3.2 ± 3.59 | -2.9 ± 4.09 | -2.9 ± 3.43 |
| Week 12; n=63, 131, 43 | -2.8 ± 3.50 | -3.6 ± 4.32 | -2.9 ± 3.68 |
| Week 16; n=65, 129, 43 | -3.4 ± 4.12 | -4.4 ± 4.62 | -4.1 ± 3.29 |
| Week 20; n=63, 127, 44 | -3.8 ± 4.06 | -5.0 ± 4.44 | -3.8 ± 3.98 |
| Week 24; n=61, 128, 43 | -4.0 ± 3.71 | -5.0 ± 4.45 | -5.0 ± 4.00 |
| Week 26; n=61, 118, 40 | -4.1 ± 3.61 | -5.4 ± 4.79 | -5.0 ± 3.18 |
| Week 28; n=62, 125, 43 | -3.7 ± 3.79 | -5.1 ± 4.74 | -5.2 ± 4.31 |
| Week 32; n=61, 125, 43 | -4.7 ± 3.87 | -5.7 ± 5.03 | -5.3 ± 3.90 |
| Week 36; n=61, 125, 43 | -5.0 ± 4.43 | -5.6 ± 5.21 | -5.0 ± 3.68 |
| Week 40; n=62, 125, 43 | -4.6 ± 4.14 | -5.8 ± 4.83 | -5.0 ± 3.78 |
| Week 44; n=62, 122, 43 | -4.7 ± 4.71 | -6.1 ± 4.47 | -5.2 ± 4.06 |
| Week 48; n=59, 122, 40 | -4.5 ± 4.16 | -6.2 ± 4.59 | -5.3 ± 4.08 |
| Week 52; n=62, 119, 39 | -5.3 ± 4.62 | -6.1 ± 4.42 | -5.6 ± 4.02 |
| Week 60; n=57, 114, 37 | -5.0 ± 4.15 | -5.8 ± 5.17 | -6.0 ± 3.94 |
| Week 64; n=60, 117, 36 | -5.1 ± 4.16 | -6.2 ± 4.96 | -5.5 ± 4.40 |
| Week 72; n=49, 103, 30 | -5.2 ± 4.32 | -6.6 ± 4.50 | -5.3 ± 4.63 |
| Week 80; n=46, 102, 36 | -5.4 ± 4.58 | -6.5 ± 4.79 | -6.0 ± 4.08 |
| Week 88; n=49, 101, 34 | -5.3 ± 4.61 | -6.5 ± 4.29 | -6.1 ± 3.80 |
| Week 96; n=49, 100, 34 | -5.6 ± 4.35 | -7.0 ± 4.44 | -6.1 ± 3.80 |
| Week 104; n=50, 104, 34 | -5.1 ± 3.69 | -7.2 ± 4.22 | -6.3 ± 3.76 |
SLEDAI-2K assessments consisted of 24 individual items with 9 organ systems. Each item was given a weighted score(1 to 8 with higher score indicating increased activity)and summed if present at the time of analysis. SLEDAI-2K score was sum of all 24 individual items from SLEDAI-2K ranges from 0(no symptoms) to 105(presence of all defined symptoms). Higher scores indicates increased disease activity. An improvement was defined as a decrease(compared to Baseline) in SLEDAI-2K score within same organ system at a post-Baseline visit. Baseline value was latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Data for following organ systems was reported: CNS total, Vascular total, Musculoskeletal total, Renal total, Mucocutaneous total, Cardiovascular (Cardio) and Respiratory (Resp) total, Immunologic total and Hematologic total. Constitutional organ system was removed from analysis and its one item (fever)moved to hematologic organ system.
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| CNS Total; Week 4; n= 2,3,2 | 0 | 33.3 | 0 |
| CNS Total; Week 8; n= 2,3,2 | 50.0 | 66.7 | 0 |
| CNS Total; Week 12; n= 2,3,2 | 50.0 | 66.7 | 50.0 |
| CNS Total; Week 16; n= 2,3,2 | 50.0 | 66.7 | 0 |
| CNS Total; Week 20; n= 2,3,2 | 100 | 66.7 | 0 |
| CNS Total; Week 24; n= 2,3,2 | 100 | 66.7 | 100 |
| CNS Total; Week 26; n= 2,3,2 | 50.0 | 66.7 | 0 |
| CNS Total; Week 28; n= 2,3,2 | 100 | 66.7 | 100 |
| CNS Total; Week 32; n= 2,3,2 | 100 | 66.7 | 100 |
| CNS Total; Week 36; n= 2,3,2 | 100 | 66.7 | 50.0 |
| CNS Total; Week 40; n= 2,3,2 | 100 | 66.7 | 100 |
| CNS Total; Week 44; n= 2,3,2 | 100 | 66.7 | 100 |
| CNS Total; Week 48; n= 2,3,2 | 100 | 66.7 | 50.0 |
| CNS Total; Week 52; n= 2,3,2 | 100 | 66.7 | 100 |
| CNS Total; Week 60; n= 2,3,2 | 100 | 66.7 | 100 |
| CNS Total; Week 64; n= 2,3,2 | 100 | 66.7 | 100 |
| CNS Total; Week 72; n= 2,3,2 | 100 | 33.3 | 50.0 |
| CNS Total; Week 80; n= 2,3,2 | 100 | 33.3 | 50.0 |
| CNS Total; Week 88; n= 2,3,2 | 100 | 33.3 | 100 |
| CNS Total; Week 96; n= 2,3,2 | 100 | 33.3 | 100 |
| CNS Total; Week 104; n=2,3,2 | 100 | 33.3 | 100 |
| Vascular Total; Week 4; n= 6,11,0 | 50.0 | 9.1 | — |
| Vascular Total; Week 8; n= 6,11,0 | 33.3 | 36.4 | — |
| Vascular Total; Week 12; n= 6,11,0 | 50.0 | 54.5 | — |
| Vascular Total; Week 16; n= 6,11,0 | 50.0 | 54.5 | — |
| Vascular Total; Week 20; n=6,11,0 | 50.0 | 72.7 | — |
| Vascular Total; Week 24; n= 6,11,0 | 50.0 | 72.7 | — |
| Vascular Total; Week 26; n= 6, 11, 0 | 50.0 | 63.6 | — |
| Vascular Total; Week 28; n= 6, 11,0 | 33.3 | 72.7 | — |
| Vascular Total; Week 32; n= 6,11, 0 | 50.0 | 72.7 | — |
| Vascular Total; Week 36; n= 6, 11,0 | 50.0 | 63.6 | — |
| Vascular Total; Week 40; n= 6, 11,0 | 33.3 | 72.7 | — |
| Vascular Total; Week 44; n= 6, 11, 0 | 33.3 | 72.7 | — |
| Vascular Total; Week 48; n= 6, 11, 0 | 33.3 | 63.6 | — |
| Vascular Total; Week 52; n= 6, 11, 0 | 66.7 | 63.6 | — |
| Vascular Total; Week 60; n= 6, 11, 0 | 50.0 | 63.6 | — |
| Vascular Total; Week 64; n= 6, 11, 0 | 50.0 | 90.9 | — |
| Vascular Total; Week 72; n= 6, 11, 0 | 33.3 | 81.8 | — |
| Vascular Total; Week 80; n= 6, 11, 0 | 50.0 | 72.7 | — |
| Vascular Total; Week 88; n= 6, 11, 0 | 50.0 | 45.5 | — |
| Vascular Total; Week 96; n= 6, 11, 0 | 50.0 | 63.6 | — |
| Vascular Total; Week 104; n= 6, 11, 0 | 33.3 | 72.7 | — |
| Musculoskeletal Total; Week 4; n= 57, 110, 34 | 22.8 | 13.6 | 23.5 |
| Musculoskeletal Total; Week 8; n=57,110, 34 | 40.4 | 40.0 | 50.0 |
| Musculoskeletal Total; Week 12; n= 57,110,34 | 36.8 | 44.5 | 47.1 |
| Musculoskeletal Total; Week 16; n= 57,110,34 | 42.1 | 56.4 | 67.6 |
| Musculoskeletal Total; Week 20; n= 57,110,34 | 47.4 | 58.2 | 64.7 |
| Musculoskeletal Total; Week 24; n= 57,110,34 | 42.1 | 54.5 | 70.6 |
| Musculoskeletal Total;; Week 26; n=57,110,34 | 43.9 | 46.4 | 73.5 |
| Musculoskeletal Total; Week 28; n= 57,110,34 | 49.1 | 53.6 | 76.5 |
| Musculoskeletal Total; Week 32; n= 57,110,34 | 54.4 | 63.6 | 76.5 |
| Musculoskeletal Total; Week 36; n= 57,110,34 | 61.4 | 61.8 | 76.5 |
| Musculoskeletal Total; Week 40; n= 57,110,34 | 54.4 | 58.2 | 73.5 |
| Musculoskeletal Total; Week 44; n= 57,110,34 | 50.9 | 60.0 | 76.5 |
| Musculoskeletal Total; Week 48; n= 57,110,34 | 57.9 | 60.9 | 73.5 |
| Musculoskeletal Total; Week 52; n= 57,110,34 | 59.6 | 59.1 | 73.5 |
| Musculoskeletal Total; Week 60; n= 57,110,34 | 54.4 | 54.5 | 67.6 |
| Musculoskeletal Total; Week 64; n= 57,110,34 | 56.1 | 55.5 | 67.6 |
| Musculoskeletal Total; Week 72; n= 57,110,34 | 47.4 | 58.2 | 58.8 |
| Musculoskeletal Total; Week 80; n= 57,110,34 | 47.4 | 58.2 | 76.5 |
| Musculoskeletal Total; Week 88; n= 57,110,34 | 57.9 | 59.1 | 67.6 |
| Musculoskeletal Total; Week 96; n= 57,110,34 | 50.9 | 60.9 | 70.6 |
| Musculoskeletal Total; Week 104; n= 57,110,34 | 47.4 | 64.5 | 67.6 |
| Renal Total; Week 4; n= 14,23,8 | 21.4 | 30.4 | 12.5 |
| Renal Total; Week 8; n= 14, 23, 8 | 50.0 | 43.5 | 12.5 |
| Renal Total; Week 12; n= 14, 23, 8 | 28.6 | 52.2 | 12.5 |
| Renal Total; Week 16; n= 14, 23, 8 | 35.7 | 52.2 | 12.5 |
| Renal Total; Week 20; n= 14, 23, 8 | 57.1 | 60.9 | 12.5 |
| Renal Total; Week 24; n= 14, 23, 8 | 35.7 | 60.9 | 12.5 |
| Renal Total; Week 26; n= 14, 23, 8 | 28.6 | 65.2 | 25.0 |
| Renal Total; Week 28; n= 14, 23, 8 | 21.4 | 56.5 | 37.5 |
| Renal Total; Week 32; n= 14, 23, 8 | 35.7 | 65.2 | 25.0 |
| Renal Total; Week 36; n= 14, 23, 8 | 42.9 | 65.2 | 50.0 |
| Renal Total; Week 40; n=14, 23, 8 | 42.9 | 69.6 | 25.0 |
| Renal Total; Week 44; n= 14, 23, 8 | 50.0 | 69.6 | 12.5 |
| Renal Total; Week 48; n=14, 23, 8 | 42.9 | 69.6 | 50.0 |
| Renal Total; Week 52; n= 14, 23, 8 | 64.3 | 69.6 | 25.0 |
| Renal Total; Week 60; n= 14, 23, 8 | 50.0 | 65.2 | 25.0 |
| Renal Total; Week 64; n= 14, 23, 8 | 50.0 | 69.6 | 12.5 |
| Renal Total; Week 72; n= 14, 23, 8 | 50.0 | 65.2 | 12.5 |
| Renal Total; Week 80; n= 14, 23, 8 | 42.9 | 65.2 | 50.0 |
| Renal Total; Week 88; n= 14, 23, 8 | 50.0 | 73.9 | 25.0 |
| Renal Total; Week 96; n= 14, 23, 8 | 35.7 | 78.3 | 37.5 |
| Renal Total; Week 104; n= 14, 23, 8 | 35.7 | 69.6 | 50.0 |
| Mucocutaneous Total; Week 4; n= 59, 126,43 | 30.5 | 28.6 | 32.6 |
| Mucocutaneous Total; Week 8; n= 59,126,43 | 54.2 | 45.2 | 51.2 |
| Mucocutaneous Total; Week 12; n= 59, 126, 43 | 55.9 | 57.1 | 55.8 |
| Mucocutaneous Total; Week 16; n= 59, 126, 43 | 57.6 | 58.7 | 67.4 |
| Mucocutaneous Total; Week 20; n= 59, 126, 43 | 50.8 | 62.7 | 69.8 |
| Mucocutaneous Total; Week 24; n= 59, 126, 43 | 59.3 | 61.9 | 69.8 |
| Mucocutaneous Total; Week 26; n=59, 126, 43 | 59.3 | 60.3 | 65.1 |
| Mucocutaneous Total; Week 28; n= 59, 126, 43 | 62.7 | 62.7 | 69.8 |
| Mucocutaneous Total; Week 32; n= 59, 126, 43 | 62.7 | 65.1 | 74.4 |
| Mucocutaneous Total; Week 36; n= 59, 126, 43 | 66.1 | 65.9 | 69.8 |
| Mucocutaneous Total; Week 40; n= 59, 126, 43 | 62.7 | 66.7 | 67.4 |
| Mucocutaneous Total; Week 44; n= 59, 126, 43 | 61.0 | 61.1 | 69.8 |
| Mucocutaneous Total; Week 48; n= 59, 126, 43 | 50.8 | 66.7 | 69.8 |
| Mucocutaneous Total; Week 52; n=59, 126, 43 | 64.4 | 64.3 | 69.8 |
| Mucocutaneous Total; Week 60; n=59, 126, 43 | 55.9 | 65.1 | 67.4 |
| Mucocutaneous Total; Week 64; n=59, 126, 43 | 64.4 | 65.9 | 62.8 |
| Mucocutaneous Total; Week 72; n=59, 126, 43 | 57.6 | 60.3 | 58.1 |
| Mucocutaneous Total; Week 80; n= 59, 126, 43 | 62.7 | 61.9 | 62.8 |
| Mucocutaneous Total; Week 88; n= 59, 126, 43 | 59.3 | 62.7 | 67.4 |
| Mucocutaneous Total; Week 96; n= 59, 126, 43 | 52.5 | 62.7 | 62.7 |
| Mucocutaneous Total; Week 104; n= 59, 126, 43 | 61.0 | 69.0 | 60.5 |
| Cardio and Resp Total; Week 4; n= 3, 7, 0 | 0 | 42.9 | — |
| Cardio and Resp Total; Week 8; n= 3, 7, 0 | 0 | 71.4 | — |
| Cardio and Resp Total; Week 12; n= 3, 7, 0 | 0 | 71.4 | — |
| Cardio and Resp Total; Week 16; n= 3, 7, 0 | 0 | 85.7 | — |
| Cardio and Resp Total; Week 20; n= 3,7, 0 | 33.3 | 71.4 | — |
| Cardio and Resp Total; Week 24; n= 3, 7, 0 | 66.7 | 100 | — |
| Cardio and Resp Total; Week 26; n=3, 7, 0 | 0 | 85.7 | — |
| Cardio and Resp Total; Week 28; n= 3,7, 0 | 0 | 85.7 | — |
| Cardio and Resp Total; Week 32; n= 3, 7, 0 | 33.3 | 100 | — |
| Cardio and Resp Total; Week 36; n= 3, 7, 0 | 66.7 | 85.7 | — |
| Cardio and Resp Total; Week 40; n=3,7, 0 | 33.3 | 71.4 | — |
| Cardio and Resp Total; Week 44; n= 3,7, 0 | 66.7 | 57.1 | — |
| Cardio and Resp Total; Week 48; n= 3, 7, 0 | 33.3 | 85.7 | — |
| Cardio and Resp Total; Week 52; n= 3, 7, 0 | 66.7 | 85.7 | — |
| Cardio and Resp Total; Week 60; n= 3,7,0 | 100 | 71.4 | — |
| Cardio and Resp Total; Week 64; n=3,7,0 | 100 | 85.7 | — |
| Cardio and Resp Total; Week 72; n= 3,7,0 | 66.7 | 71.4 | — |
| Cardio and Resp Total; Week 80; n=3,7,0 | 66.7 | 85.7 | — |
| Cardio and Resp Total; Week 88; n= 3,7,0 | 66.7 | 71.4 | — |
| Cardio and Resp Total; Week 96; n= 3,7,0 | 66.7 | 71.4 | — |
| Cardio and Resp Total; Week 104; n= 3,7,0 | 66.7 | 71.4 | — |
| Immunologic Total; Week 4; n=48, 104, 34 | 12.5 | 10.6 | 17.6 |
| Immunologic Total; Week 8; n= 48, 104, 34 | 16.7 | 17.3 | 17.6 |
| Immunologic Total; Week 12; n= 48, 104, 34 | 22.9 | 24.0 | 17.6 |
| Immunologic Total; Week 16; n= 48, 104, 34 | 20.8 | 30.8 | 11.8 |
| Immunologic Total; Week 20; n= 48, 104, 34 | 20.8 | 36.5 | 23.5 |
| Immunologic Total; Week 24; n= 48, 104, 34 | 22.9 | 34.6 | 20.6 |
| Immunologic Total; Week 26; n= 48, 104, 34 | 18.8 | 39.4 | 11.8 |
| Immunologic Total; Week 28; n= 48, 104, 34 | 18.8 | 34.6 | 20.6 |
| Immunologic Total; Week 32; n= 48, 104, 34 | 25.0 | 40.4 | 23.5 |
| Immunologic Total; Week 36; n= 48, 104, 34 | 20.8 | 41.3 | 17.6 |
| Immunologic Total; Week 40; n= 48, 104, 34 | 14.6 | 44.2 | 23.5 |
| Immunologic Total; Week 44; n= 48, 104, 34 | 25.0 | 39.4 | 38.2 |
| Immunologic Total; Week 48; n= 48, 104, 34 | 20.8 | 41.3 | 29.4 |
| Immunologic Total; Week 52; n= 48, 104, 34 | 20.8 | 37.5 | 26.5 |
| Immunologic Total; Week 60; n= 48, 104, 34 | 25.0 | 45.2 | 20.6 |
| Immunologic Total; Week 64; n= 48, 104, 34 | 20.8 | 43.3 | 26.5 |
| Immunologic Total; Week 72; n=48, 104, 34 | 29.2 | 36.5 | 17.6 |
| Immunologic Total; Week 80; n=48, 104, 34 | 22.9 | 31.7 | 23.5 |
| Immunologic Total; Week 88; n=48, 104, 34 | 31.3 | 29.8 | 14.7 |
| Immunologic Total; Week 96; n=48, 104, 34 | 20.8 | 33.7 | 20.6 |
| Immunologic Total; Week 104; n=48, 104, 34 | 27.1 | 40.4 | 20.6 |
| Hematologic Total; Week 4; n= 8, 19, 3 | 50.0 | 42.1 | 0 |
| Hematologic Total; Week 8; n= 8, 19, 3 | 62.5 | 63.2 | 66.7 |
| Hematologic Total; Week 12; n= 8, 19, 3 | 62.5 | 52.6 | 33.3 |
| Hematologic Total; Week 16; n= 8, 19, 3 | 75.0 | 63.2 | 66.7 |
| Hematologic Total; Week 20; n= 8, 19, 3 | 87.5 | 57.9 | 100 |
| Hematologic Total; Week 24; n= 8, 19, 3 | 62.5 | 52.6 | 100 |
| Hematologic Total; Week 26; n= 8, 19, 3 | 75.0 | 36.8 | 100 |
| Hematologic Total; Week 28; n= 8, 19, 3 | 62.5 | 57.9 | 66.7 |
| Hematologic Total; Week 32; n= 8, 19, 3 | 62.5 | 57.9 | 66.7 |
| Hematologic Total; Week 36; n= 8, 19, 3 | 87.5 | 63.2 | 66.7 |
| Hematologic Total; Week 40; n= 8, 19, 3 | 62.5 | 52.6 | 66.7 |
| Hematologic Total; Week 44; n= 8, 19, 3 | 87.5 | 57.9 | 66.7 |
| Hematologic Total; Week 48; n= 8, 19, 3 | 37.5 | 63.2 | 66.7 |
| Hematologic Total; Week 52; n= 8, 19, 3 | 75.0 | 52.6 | 33.3 |
| Hematologic Total; Week 60; n= 8, 19, 3 | 50.0 | 57.9 | 33.3 |
| Hematologic Total; Week 64; n= 8, 19, 3 | 62.5 | 68.4 | 33.3 |
| Hematologic Total; Week 72; n= 8, 19, 3 | 62.5 | 47.4 | 0 |
| Hematologic Total; Week 80; n= 8, 19, 3 | 50.0 | 52.6 | 33.3 |
| Hematologic Total; Week 88; n= 8, 19, 3 | 37.5 | 57.9 | 33.3 |
| Hematologic Total; Week 96; n= 8, 19, 3 | 50.0 | 52.6 | 33.3 |
| Hematologic Total; Week 104; n= 8, 19, 3 | 50.0 | 63.2 | 33.3 |
SLEDAI-2K assessments consisted of 24 individual items with 9 organ systems. Each item was given a weighted score(1 to 8 with higher score indicating increased activity)and summed if present at time of analysis. SLEDAI-2K score was sum of all 24 individual items from SLEDAI-2K, ranges from 0(no symptoms) to 105(presence of all defined symptoms). Higher scores indicates increased disease activity. A worsening was defined as an increase(compared to Baseline) in SLEDAI-2K score within same organ system at a post-Baseline visit. Baseline value was latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Percentage of participants with SLEDAI-2K organ worsening for following organ systems were reported;CNS total,Vascular total,Musculoskeletal total,Renal total,Mucocutaneous total,Cardio and Resp total,Immunologic total and Hematologic total. Constitutional organ system was removed from analysis and its one item (fever)moved to hematologic organ system.
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| CNS Total; Week 4; n= 69, 136, 43 | 0 | 0 | 0 |
| CNS Total; Week 8; n= 64,132, 42 | 0 | 0 | 0 |
| CNS Total; Week 12; n= 65, 134, 42 | 0 | 0 | 0 |
| CNS Total; Week 16; n= 65, 130, 42 | 0 | 0.8 | 0 |
| CNS Total; Week 20; n= 63, 128, 42 | 0 | 0 | 0 |
| CNS Total; Week 24; n= 61, 127, 41 | 0 | 0.8 | 0 |
| CNS Total; Week 26; n=61, 116, 38 | 0 | 0.9 | 0 |
| CNS Total; Week 28; n=62, 124, 41 | 0 | 0 | 0 |
| CNS Total; Week 32; n= 61, 124, 41 | 0 | 0.8 | 0 |
| CNS Total; Week 36; n=61, 124, 41 | 0 | 1.6 | 0 |
| CNS Total; Week 40; n=61, 123, 41 | 0 | 0 | 0 |
| CNS Total; Week 44; n= 61, 121, 41 | 0 | 0 | 0 |
| CNS Total; Week 48; n= 58, 120,39 | 0 | 0 | 0 |
| CNS Total; Week 52; n= 62, 120, 38 | 0 | 0 | 0 |
| CNS Total; Week 60; n=59, 117, 35 | 0 | 0 | 0 |
| CNS Total; Week 64; n=60, 117, 34 | 0 | 0 | 0 |
| CNS Total; Week 72; n= 56, 109, 31 | 0 | 0 | 0 |
| CNS Total; Week 80; n=55, 111, 35 | 0 | 0 | 0 |
| CNS Total; Week 88; n= 57, 107, 34 | 0 | 0 | 0 |
| CNS Total; Week 96; n=52, 107, 33 | 0 | 0 | 0 |
| CNS Total; Week 104; n= 53, 112, 34 | 0 | 0 | 0 |
| Vascular Total;Week 4; n= 65, 128, 45 | 0 | 3.9 | 0 |
| Vascular Total;Week 8; n= 61, 124, 44 | 0 | 2.4 | 0 |
| Vascular Total; Week 12; n= 62, 126, 44 | 1.6 | 1.6 | 0 |
| Vascular Total; Week 16; n=62, 122, 44 | 0 | 1.6 | 0 |
| Vascular Total; Week 20; n=60, 120, 44 | 0 | 0.8 | 0 |
| Vascular Total; Week 24; n= 59, 119, 43 | 0 | 0 | 0 |
| Vascular Total; Week 26; n=58, 109, 40 | 0 | 0.9 | 0 |
| Vascular Total;Week 28; n= 61, 116, 43 | 0 | 1.7 | 0 |
| Vascular Total;Week 32; n=59, 116, 43 | 0 | 2.6 | 0 |
| Vascular Total;Week 36; n= 59, 116, 43 | 0 | 1.7 | 0 |
| Vascular Total;Week 40; n=59, 115, 43 | 0 | 1.7 | 0 |
| Vascular Total;Week 44; n= 59, 113, 43 | 0 | 0 | 0 |
| Vascular Total;Week 48; n= 57, 112, 40 | 0 | 0 | 0 |
| Vascular Total;Week 52; n=60, 112, 40 | 0 | 0.9 | 0 |
| Vascular Total;Week 60; n= 58, 109, 37 | 0 | 0 | 0 |
| Vascular Total;Week 64; n=59, 109, 36 | 0 | 1.8 | 0 |
| Vascular Total;Week 72; n=55, 101, 33 | 0 | 0 | 0 |
| Vascular Total;Week 80; n= 54, 104, 37 | 0 | 1.0 | 0 |
| Vascular Total;Week 88; n=56, 102, 36 | 0 | 0 | 0 |
| Vascular Total;Week 96; n=51, 101, 35 | 0 | 0 | 0 |
| Vascular Total;Week 104; n=53, 105, 36 | 0 | 0 | 0 |
| Musculoskeletal Total; Week 4; n=15, 33, 12 | 0 | 12.1 | 0 |
| Musculoskeletal Total; Week 8; n= 15, 33, 12 | 6.7 | 6.1 | 0 |
| Musculoskeletal Total; Week 12; n= 15, 33, 12 | 13.3 | 6.1 | 0 |
| Musculoskeletal Total; Week 16; n= 15, 32, 12 | 6.7 | 3.1 | 8.3 |
| Musculoskeletal Total; Week 20; n= 15, 32, 12 | 6.7 | 6.3 | 0 |
| Musculoskeletal Total; Week 24; n= 15, 31, 11 | 0 | 6.5 | 0 |
| Musculoskeletal Total; Week 26; n= 15, 31, 11 | 0 | 3.2 | 0 |
| Musculoskeletal Total; Week 28; n= 14, 31, 11 | 0 | 3.2 | 9.1 |
| Musculoskeletal Total; Week 32; n= 15, 30, 11 | 0 | 6.7 | 9.1 |
| Musculoskeletal Total; Week 36; n= 14, 30, 11 | 7.1 | 3.3 | 9.1 |
| Musculoskeletal Total; Week 40; n=15, 30, 11 | 0 | 3.3 | 9.1 |
| Musculoskeletal Total; Week 44; n=15, 29, 11 | 0 | 6.9 | 9.1 |
| Musculoskeletal Total; Week 48; n= 14, 30, 10 | 7.1 | 3.3 | 10.0 |
| Musculoskeletal Total; Week 52; n= 15, 30, 11 | 6.7 | 6.7 | 9.1 |
| Musculoskeletal Total; Week 60; n= 14, 28, 11 | 0 | 0 | 9.1 |
| Musculoskeletal Total; Week 64; n=14, 29, 10 | 0 | 3.4 | 10.0 |
| Musculoskeletal Total; Week 72; n= 14, 27, 10 | 0 | 11.1 | 10.0 |
| Musculoskeletal Total; Week 80; n= 13, 26, 9 | 0 | 0 | 11.1 |
| Musculoskeletal Total; Week 88; n= 13, 25, 9 | 15.4 | 4.0 | 0 |
| Musculoskeletal Total; Week 96; n= 12, 26, 9 | 0 | 3.8 | 0 |
| Musculoskeletal Total; Week 104; n= 13, 27, 9 | 0 | 0 | 0 |
| Renal Total; Week 4; n= 57, 117, 36 | 5.3 | 6.0 | 11.1 |
| Renal Total; Week 8; n=51, 110, 36 | 2.0 | 3.6 | 5.6 |
| Renal Total; Week 12; n=53, 115, 35 | 1.9 | 3.5 | 8.6 |
| Renal Total; Week 16; n=53, 112, 35 | 7.5 | 4.5 | 2.9 |
| Renal Total; Week 20; n= 49, 108, 36 | 8.2 | 3.7 | 8.3 |
| Renal Total; Week 24; n= 49, 111, 35 | 10.2 | 3.6 | 2.9 |
| Renal Total; Week 26; n= 49, 99, 33 | 6.1 | 0 | 0 |
| Renal Total; Week 28; n= 50, 106, 36 | 10.0 | 1.9 | 2.8 |
| Renal Total; Week 32; n= 50,107, 36 | 6.0 | 2.8 | 2.8 |
| Renal Total; Week 36; n= 50, 107, 36 | 8.0 | 2.8 | 5.6 |
| Renal Total; Week 40; n= 47, 106, 34 | 6.4 | 4.7 | 0 |
| Renal Total; Week 44; n= 49, 103, 35 | 6.1 | 1.0 | 2.9 |
| Renal Total; Week 48; n= 47, 101, 32 | 10.6 | 5.9 | 6.3 |
| Renal Total; Week 52; n= 49, 103, 32 | 8.2 | 3.9 | 3.1 |
| Renal Total; Week 60; n=47, 96, 30 | 6.4 | 4.2 | 0 |
| Renal Total; Week 64; n= 50, 99, 29 | 2.0 | 2.0 | 0 |
| Renal Total; Week 72; n= 40, 89, 26 | 5.0 | 4.5 | 0 |
| Renal Total; Week 80; n= 41, 90, 29 | 14.6 | 3.3 | 6.9 |
| Renal Total; Week 88; n= 44, 85, 29 | 13.6 | 1.2 | 0 |
| Renal Total; Week 96; n= 43, 85, 29 | 4.7 | 1.2 | 0 |
| Renal Total; Week 104; n= 44, 90, 30 | 6.8 | 2.2 | 0 |
| Mucocutaneous Total; Week 4; n= 13, 18, 4 | 15.4 | 5.6 | 0 |
| Mucocutaneous Total; Week 8; n= 12, 18, 4 | 8.3 | 11.1 | 0 |
| Mucocutaneous Total; Week 12; n= 12, 18, 4 | 8.3 | 16.7 | 0 |
| Mucocutaneous Total; Week 16; n= 12, 18, 4 | 0 | 5.6 | 0 |
| Mucocutaneous Total; Week 20; n= 12, 18, 4 | 25.0 | 5.6 | 0 |
| Mucocutaneous Total; Week 24; n= 11, 17, 4 | 18.2 | 5.9 | 0 |
| Mucocutaneous Total; Week 26; n= 10, 17, 4 | 20.0 | 11.8 | 0 |
| Mucocutaneous Total; Week 28; n= 10, 17, 4 | 0 | 11.8 | 0 |
| Mucocutaneous Total; Week 32; n= 10, 17, 4 | 10.0 | 5.9 | 0 |
| Mucocutaneous Total; Week 36; n= 10, 17, 4 | 0 | 5.9 | 0 |
| Mucocutaneous Total; Week 40; n= 10, 17, 4 | 20.0 | 11.8 | 0 |
| Mucocutaneous Total; Week 44; n= 10, 17, 4 | 10.0 | 0 | 0 |
| Mucocutaneous Total; Week 48; n=10, 16, 3 | 0 | 6.3 | 0 |
| Mucocutaneous Total; Week 52; n= 10, 17, 4 | 0 | 5.9 | 25.0 |
| Mucocutaneous Total; Week 60; n= 9, 17, 4 | 11.1 | 11.8 | 0 |
| Mucocutaneous Total; Week 64; n= 10, 16, 4 | 0 | 6.3 | 25.0 |
| Mucocutaneous Total; Week 72; n=10, 16, 4 | 20 | 6.3 | 25.0 |
| Mucocutaneous Total; Week 80; n= 9, 17, 4 | 0 | 0 | 25.0 |
| Mucocutaneous Total; Week 88; n= 9, 16, 4 | 0 | 6.3 | 25.0 |
| Mucocutaneous Total; Week 96; n= 9, 15, 4 | 11.1 | 0 | 25.0 |
| Mucocutaneous Total; Week 104; n= 9, 17, 4 | 11.1 | 5.9 | 0 |
| Cardio and Resp Total; Week 4; n= 68, 132, 45 | 2.9 | 0.8 | 0 |
| Cardio and Resp Total; Week 8; n= 63, 128, 44 | 0 | 0.8 | 0 |
| Cardio and Resp Total; Week 12; n= 64, 130, 44 | 0 | 0.8 | 0 |
| Cardio and Resp Total; Week 16; n= 64, 126, 44 | 3.1 | 0 | 0 |
| Cardio and Resp Total; Week 20; n= 63, 124, 44 | 1.6 | 0.8 | 0 |
| Cardio and Resp Total; Week 24; n= 60, 123, 43 | 0 | 0 | 0 |
| Cardio and Resp Total; Week 26; n=59, 112, 40 | 0 | 0 | 0 |
| Cardio and Resp Total; Week 28; n= 61, 120, 43 | 3.3 | 0.8 | 0 |
| Cardio and Resp Total; Week 32; n= 60, 120, 43 | 1.7 | 0 | 0 |
| Cardio and Resp Total; Week 36; n= 60, 120, 43 | 1.7 | 0 | 0 |
| Cardio and Resp Total; Week 40; n=60, 119, 43 | 0 | 0 | 0 |
| Cardio and Resp Total; Week 44; n= 60, 117, 43 | 1.7 | 0 | 0 |
| Cardio and Resp Total; Week 48; n= 57, 116, 40 | 0 | 0 | 2.5 |
| Cardio and Resp Total; Week 52; n=61, 116, 40 | 0 | 0 | 0 |
| Cardio and Resp Total; Week 60; n= 58, 114, 37 | 0 | 0 | 0 |
| Cardio and Resp Total; Week 64; n= 59, 114, 36 | 0 | 0.9 | 0 |
| Cardio and Resp Total; Week 72; n= 55, 106, 33 | 0 | 0 | 0 |
| Cardio and Resp Total; Week 80; n= 54, 107, 37 | 1.9 | 0 | 0 |
| Cardio and Resp Total; Week 88; n= 56, 104, 36 | 1.8 | 0 | 0 |
| Cardio and Resp Total; Week 96; n=51, 104, 35 | 0 | 1.0 | 0 |
| Cardio and Resp Total; Week 104; n= 52, 109, 36 | 0 | 0 | 0 |
| Immunologic Total; Week 4; n=23, 37, 13 | 17.4 | 0 | 7.7 |
| Immunologic Total; Week 8; n=20, 37, 12 | 20.0 | 10.8 | 0 |
| Immunologic Total; Week 12; n=21, 37,12 | 23.8 | 8.1 | 16.7 |
| Immunologic Total; Week 16; n= 21, 35, 12 | 9.5 | 11.4 | 0 |
| Immunologic Total; Week 20; n= 19, 35, 12 | 15.8 | 11.4 | 0 |
| Immunologic Total; Week 24; n= 18, 35, 12 | 5.6 | 5.7 | 0 |
| Immunologic Total; Week 26; n= 18, 30, 12 | 5.6 | 6.7 | 8.3 |
| Immunologic Total; Week 28; n= 19, 35, 12 | 15.8 | 8.6 | 16.7 |
| Immunologic Total; Week 32; n= 19, 33, 12 | 10.5 | 12.1 | 8.3 |
| Immunologic Total; Week 36; n= 19, 34, 12 | 15.8 | 8.8 | 16.7 |
| Immunologic Total; Week 40; n= 19, 33, 12 | 21.1 | 6.1 | 8.3 |
| Immunologic Total; Week 44; n= 18, 33, 12 | 22.2 | 0 | 0 |
| Immunologic Total; Week 48; n= 18, 33, 11 | 22.2 | 3.0 | 27.3 |
| Immunologic Total; Week 52; n= 19, 32, 12 | 21.1 | 3.1 | 8.3 |
| Immunologic Total; Week 60; n= 18, 32, 10 | 16.7 | 6.3 | 0 |
| Immunologic Total; Week 64; n= 19, 33, 10 | 21.1 | 6.1 | 20.0 |
| Immunologic Total; Week 72; n= 17, 28, 9 | 23.5 | 7.1 | 11.1 |
| Immunologic Total; Week 80; n= 18, 29, 11 | 5.6 | 6.9 | 18.2 |
| Immunologic Total; Week 88; n= 19, 29, 11 | 10.5 | 6.9 | 18.2 |
| Immunologic Total; Week 96; n= 16, 30, 11 | 12.5 | 13.3 | 18.2 |
| Immunologic Total; Week 104; n= 17, 28, 12 | 11.8 | 17.9 | 16.7 |
| Hematologic Total; Week 4; n= 59, 115, 40 | 5.1 | 3.5 | 5.0 |
| Hematologic Total; Week 8; n= 52, 109, 38 | 3.8 | 5.5 | 0 |
| Hematologic Total; Week 12; n= 55, 110, 38 | 1.8 | 4.5 | 10.5 |
| Hematologic Total; Week 16; n=54, 107, 34 | 1.9 | 2.8 | 2.9 |
| Hematologic Total; Week 20; n= 54, 108, 40 | 5.6 | 5.6 | 5.0 |
| Hematologic Total; Week 24; n= 53, 111, 37 | 3.8 | 2.7 | 2.7 |
| Hematologic Total; Week 26; n= 53, 101, 37 | 9.4 | 5.0 | 10.8 |
| Hematologic Total; Week 28; n= 52, 106, 39 | 7.7 | 3.8 | 5.1 |
| Hematologic Total; Week 32; n=52, 110, 38 | 0 | 4.5 | 7.9 |
| Hematologic Total; Week 36; n= 53, 109, 40 | 5.7 | 6.4 | 2.5 |
| Hematologic Total; Week 40; n= 51, 108, 37 | 0 | 10.2 | 5.4 |
| Hematologic Total; Week 44; n=53, 107, 38 | 7.5 | 6.5 | 5.3 |
| Hematologic Total; Week 48; n=51, 105, 35 | 5.9 | 4.8 | 0 |
| Hematologic Total; Week 52; n= 53, 103, 37 | 3.8 | 3.9 | 2.7 |
| Hematologic Total; Week 60; n=53, 101, 35 | 9.4 | 5.0 | 5.7 |
| Hematologic Total; Week 64; n=54, 98, 32 | 11.1 | 5.1 | 6.3 |
| Hematologic Total; Week 72; n= 47,96, 29 | 10.6 | 5.2 | 3.4 |
| Hematologic Total; Week 80; n= 45, 94, 35 | 0 | 4.3 | 5.7 |
| Hematologic Total; Week 88; n= 46, 88, 32 | 10.9 | 9.1 | 3.1 |
| Hematologic Total; Week 96; n= 45, 90, 32 | 4.4 | 4.4 | 3.1 |
| Hematologic Total; Week 104; n= 46, 94, 32 | 4.3 | 6.4 | 6.3 |
The Physician's Global Assessment (PGA) was a physician-reported visual analogue scale that provides an overall measure of the participant's current disease activity. Physician's Global Assessment was collected on a 10 centimeter (cm) visual analogue scale (VAS) by placing a mark on the scale between 0 (no disease activity) to 10 (maximum disease activity). The PGA score was then rescaled for reporting by multiplying the collected score by 3 divided by 10. Hence, the PGA score ranges from 0 to 3 with higher scores indicating greater disease activity. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as the post-dose visit value minus Baseline value.
| Scores on a scale | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Week 4; n=72, 142, 45 | -0.285 ± 0.4816 | -0.247 ± 0.4640 | -0.303 ± 0.5464 |
| Week 8; n=66, 135, 44 | -0.535 ± 0.5134 | -0.520 ± 0.5243 | -0.585 ± 0.5793 |
| Week 12; n=66, 137, 44 | -0.592 ± 0.5265 | -0.660 ± 0.5776 | -0.654 ± 0.5450 |
| Week 16; n=68, 132, 44 | -0.619 ± 0.5475 | -0.717 ± 0.5802 | -0.759 ± 0.6072 |
| Week 20; n=66, 130, 44 | -0.697 ± 0.6157 | -0.787 ± 0.5445 | -0.786 ± 0.6772 |
| Week 24; n=62, 130, 43 | -0.770 ± 0.5888 | -0.766 ± 0.5059 | -0.965 ± 0.6413 |
| Week 26; n=62, 120, 40 | -0.786 ± 0.5727 | -0.811 ± 0.5445 | -0.929 ± 0.6631 |
| Week 28; n=63, 127, 43 | -0.781 ± 0.5395 | -0.817 ± 0.5360 | -0.980 ± 0.6286 |
| Week 32; n=62, 124, 43 | -0.851 ± 0.5989 | -0.864 ± 0.5519 | -1.005 ± 0.6723 |
| Week 36; n=64, 126, 43 | -0.916 ± 0.6141 | -0.927 ± 0.5400 | -0.917 ± 0.5504 |
| Week 40; n=63, 126, 43 | -0.893 ± 0.6157 | -0.925 ± 0.5621 | -0.993 ± 0.6711 |
| Week 44; n=63, 124, 43 | -0.800 ± 0.6764 | -0.905 ± 0.5289 | -0.970 ± 0.6065 |
| Week 48; n=59, 121, 40 | -0.885 ± 0.6178 | -0.928 ± 0.5627 | -0.956 ± 0.5175 |
| Week 52; n=64, 122, 41 | -0.947 ± 0.6918 | -0.938 ± 0.6125 | -1.004 ± 0.5527 |
| Week 60; n=61, 120, 37 | -0.836 ± 0.6982 | -0.848 ± 0.6085 | -1.206 ± 0.5917 |
| Week 64; n=62, 120, 36 | -0.876 ± 0.6971 | -0.943 ± 0.5711 | -1.095 ± 0.6365 |
| Week 72; n=58, 110, 33 | -0.928 ± 0.6838 | -0.944 ± 0.5708 | -1.047 ± 0.6088 |
| Week 80; n=57, 112, 37 | -0.949 ± 0.6909 | -0.954 ± 0.6221 | -1.138 ± 0.5574 |
| Week 88; n=59, 109, 36 | -1.060 ± 0.6307 | -0.993 ± 0.5733 | -1.140 ± 0.5514 |
| Week 96; n=54, 109, 35 | -1.016 ± 0.6093 | -0.994 ± 0.5669 | -1.214 ± 0.5580 |
| Week 104; n=55, 114, 36 | -1.052 ± 0.5095 | -1.074 ± 0.5166 | -1.085 ± 0.5987 |
The SLICC-ACR Damage Index measures irreversible (not related to active inflammation) changes occurring since the diagnosis of SLE ascertained by clinical assessment and present for at least 6 months. The questionnaire contains 39 items covering 12 different organ systems which were scored on a numerical scale between 0 (no damage) to 7 (increasing disease damage). Individual ranges for organ systems were; ocular: 0-2, neuropsychiatric: 0-6, renal: 0-3, pulmonary: 0-5, cardiovascular:0-6, peripheral vascular: 0-5, gastrointestinal:0-5, musculoskeletal: 0-6, skin: 0-3, endocrine (diabetes): 0-1, gonadal:0-1 and malignancies: 0-2. The SLICC-ACR score was calculated by taking sum of the individual scores for 12 organ systems which ranges from 0 (no damage) to 45 (increasing disease damage) where higher score indicates increasing disease damage severity. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits.
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Week 52 | 1.4 (0 to 4.1) | 2.1 (0 to 4.4) | 2.1 (0 to 6.3) |
| Week 104 | 5.6 (0.3 to 10.8) | 5.6 (1.8 to 9.3) | 6.4 (0 to 13.4) |
Lupus low disease activity state (LLDAS) was defined as a state which, if sustained, was associated with a low likelihood of adverse outcome, considering disease activity and medication safety. The LLDAS response criteria were: (1) SLEDAI-2K \<=4, with no activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis, fever) and no hemolytic anemia or gastrointestinal activity; (2) no new features of lupus disease activity compared with the previous assessment; (3) PGA (scale 0-3), \<=1; (4) current prednisolone (or equivalent) dose \<=7.5 mg daily; and (5) well tolerated standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs. Percentage of participants that met the LLDAS response criteria were reported.
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Week 4 | 0 (NA to NA) | 2.1 (0 to 4.4) | 2.1 (0 to 6.3) |
| Week 8 | 9.7 (2.9 to 16.6) | 1.4 (0 to 3.3) | 10.6 (1.8 to 19.5) |
| Week 12 | 8.3 (1.9 to 14.7) | 9.7 (4.9 to 14.6) | 6.4 (0 to 13.4) |
| Week 16 | 11.1 (3.9 to 18.4) | 16.7 (10.6 to 22.8) | 19.1 (7.9 to 30.4) |
| Week 20 | 11.1 (3.9 to 18.4) | 25.7 (18.6 to 32.8) | 19.1 (7.9 to 30.4) |
| Week 24 | 12.5 (4.9 to 20.1) | 22.2 (15.4 to 29.0) | 36.2 (22.4 to 49.9) |
| Week 26 | 22.2 (12.6 to 31.8) | 25.7 (18.6 to 32.8) | 34.0 (20.5 to 47.6) |
| Week 28 | 20.8 (11.5 to 30.2) | 25.0 (17.9 to 32.1) | 34.0 (20.5 to 47.6) |
| Week 32 | 29.2 (18.7 to 39.7) | 31.9 (24.3 to 39.6) | 36.2 (22.4 to 49.9) |
| Week 36 | 30.6 (19.9 to 41.2) | 34.0 (26.3 to 41.8) | 29.8 (16.7 to 42.9) |
| Week 40 | 22.2 (12.6 to 31.8) | 33.3 (25.6 to 41.0) | 38.3 (24.4 to 52.2) |
| Week 44 | 30.6 (19.9 to 41.2) | 37.5 (29.6 to 45.4) | 31.9 (18.6 to 45.2) |
| Week 48 | 26.4 (16.2 to 36.6) | 37.5 (29.6 to 45.4) | 31.9 (18.6 to 45.2) |
| Week 52 | 27.8 (17.4 to 38.1) | 34.0 (26.3 to 41.8) | 29.8 (16.7 to 42.9) |
| Week 60 | 26.4 (16.2 to 36.6) | 23.6 (16.7 to 30.5) | 36.2 (22.4 to 49.9) |
| Week 64 | 20.8 (11.5 to 30.2) | 30.6 (23.0 to 38.1) | 31.9 (18.6 to 45.2) |
| Week 72 | 22.2 (12.6 to 31.8) | 31.3 (23.7 to 38.8) | 31.9 (18.6 to 45.2) |
| Week 80 | 18.1 (9.2 to 26.9) | 26.4 (19.2 to 33.6) | 34.0 (20.5 to 47.6) |
| Week 88 | 23.6 (13.8 to 33.4) | 24.3 (17.3 to 31.3) | 29.8 (16.7 to 42.9) |
| Week 96 | 20.8 (11.5 to 30.2) | 30.6 (23.0 to 38.1) | 36.2 (22.4 to 49.9) |
| Week 104 | 20.8 (11.5 to 30.2) | 32.6 (25.0 to 40.3) | 38.3 (24.4 to 52.2) |
Percentage of participants with a state of disease control was defined as the percentage of participants with a SLEDAI-2K score \<=2, achieved without immunosuppressants and with corticosteroids at a prednisone equivalent dose of \<=5 mg/day, using the PI assessment of SLEDAI-2K. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. SLEDAI-2K score was the sum of all 24 individual items from SLEDAI-2K, ranges from 0 (no symptoms) to 105 (presence of all defined symptoms), higher scores representing increased disease activity. Percentage of participants with a state of disease control using the PI assessment of SLEDAI-2K were summarized.
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Week 4 | 2.8 (0 to 6.6) | 3.5 (0.5 to 6.5) | 8.5 (0.5 to 16.5) |
| Week 8 | 13.9 (5.9 to 21.9) | 9.0 (4.3 to 13.7) | 21.3 (9.6 to 33.0) |
| Week 12 | 11.1 (3.9 to 18.4) | 12.5 (7.1 to 17.9) | 19.1 (7.9 to 30.4) |
| Week 16 | 15.3 (7.0 to 23.6) | 22.2 (15.4 to 29.0) | 29.8 (16.7 to 42.9) |
| Week 20 | 13.9 (5.9 to 21.9) | 24.3 (17.3 to 31.3) | 31.9 (18.6 to 45.2) |
| Week 24 | 18.1 (9.2 to 26.9) | 25.0 (17.9 to 32.1) | 34.0 (20.5 to 47.6) |
| Week 26 | 15.3 (7.0 to 23.6) | 25.7 (18.6 to 32.8) | 25.5 (13.1 to 38.0) |
| Week 28 | 11.1 (3.9 to 18.4) | 25.7 (18.6 to 32.8) | 36.2 (22.4 to 49.9) |
| Week 32 | 15.3 (7.0 to 23.6) | 28.5 (21.1 to 35.8) | 31.9 (18.6 to 45.2) |
| Week 36 | 19.4 (10.3 to 28.6) | 27.8 (20.5 to 35.1) | 27.7 (14.9 to 40.4) |
| Week 40 | 16.7 (8.1 to 25.3) | 24.3 (17.3 to 31.3) | 23.4 (11.3 to 35.5) |
| Week 44 | 18.1 (9.2 to 26.9) | 26.4 (19.2 to 33.6) | 27.7 (14.9 to 40.4) |
| Week 48 | 18.1 (9.2 to 26.9) | 26.4 (19.2 to 33.6) | 27.7 (14.9 to 40.4) |
| Week 52 | 19.4 (10.3 to 28.6) | 20.1 (13.6 to 26.7) | 27.7 (14.9 to 40.4) |
| Week 60 | 18.1 (9.2 to 26.9) | 20.8 (14.2 to 27.5) | 23.4 (11.3 to 35.5) |
| Week 64 | 11.1 (3.9 to 18.4) | 18.1 (11.8 to 24.3) | 27.7 (14.9 to 40.4) |
| Week 72 | 9.7 (2.9 to 16.6) | 12.5 (7.1 to 17.9) | 23.4 (11.3 to 35.5) |
| Week 80 | 8.3 (1.9 to 14.7) | 13.2 (7.7 to 18.7) | 31.9 (18.6 to 45.2) |
| Week 88 | 11.1 (3.9 to 18.4) | 9.7 (4.9 to 14.6) | 21.3 (9.6 to 33.0) |
| Week 96 | 8.3 (1.9 to 14.7) | 12.5 (7.1 to 17.9) | 31.9 (18.6 to 45.2) |
| Week 104 | 8.3 (1.9 to 14.7) | 11.8 (6.5 to 17.1) | 23.4 (11.3 to 35.5) |
Percentage of participants with a state of clinical remission was defined as the percentage of participants with a clinical SLEDAI-2K score =0 (does not include anti-dsDNA and complement activity scores), achieved without immunosuppressants (which was allowed in Belimumab+ Standard therapy arm only) and with corticosteroids at a prednisone equivalent dose of 0 mg/day using the PI assessment of SLEDAI-2K. SLEDAI-2K consisted of 24 individual items within each of 9 organ systems. Each item was given a weighted score (1 to 8, higher score indicates increased activity) and summed if present at the time of visit or in preceding 10 days. The clinical SLEDAI-2K score was sum of 22 out of all 24 individual items from the SLEDAI-2K and ranges from 0 (no symptoms) to 101 (presence of all defined symptoms) with higher scores representing increased disease activity. Percentage of participants with a state of clinical remission using the PI assessment of SLEDAI-2K were summarized.
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Week 60 | 6.9 (1.1 to 12.8) | 3.5 (0.5 to 6.5) | 10.6 (1.8 to 19.5) |
| Week 64 | 6.9 (1.1 to 12.8) | 5.6 (1.8 to 9.3) | 10.6 (1.8 to 19.5) |
| Week 72 | 6.9 (1.1 to 12.8) | 3.5 (0.5 to 6.5) | 14.9 (4.7 to 25.1) |
| Week 80 | 6.9 (1.1 to 12.8) | 4.2 (0.9 to 7.4) | 14.9 (4.7 to 25.1) |
| Week 88 | 6.9 (1.1 to 12.8) | 2.1 (0 to 4.4) | 14.9 (4.7 to 25.1) |
| Week 96 | 4.2 (0 to 8.8) | 4.2 (0.9 to 7.4) | 12.8 (3.2 to 22.3) |
| Week 104 | 2.8 (0 to 6.6) | 3.5 (0.5 to 6.5) | 6.4 (0 to 13.4) |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situations as per medical or scientific judgment. Data for number of participants with SAE and non-SAE (\>=5 %) has been summarized.
| Participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| SAE | 10 | 32 | 15 |
| non-SAE | 48 | 109 | 53 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. AESIs were Malignant Neoplasms, Post-Injection Systemic Reactions (PISR), All Infections of Special Interest (Opportunistic Infections (OI), Herpes Zoster (HZ), Tuberculosis (TB), and Sepsis), Depression (including mood disorders and anxiety)/suicide/self-injury and Deaths. Data for number of participants with AESIs has been summarized.
| Participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Malignant Neoplasms | 1 | 1 | 1 |
| PISR | 7 | 19 | 4 |
| All Infections of Special Interest | 5 | 12 | 5 |
| Depression/suicide/self-injury | 9 | 16 | 5 |
| Deaths | 1 | 2 | 0 |
The Patient's Global Assessment (PtGA) of Disease Activity is a single-item, participant reported scale developed for the assessment of the participant's overall rating of their disease activity due to SLE. The scale measures disease activity ranging from 0 (Very Well) to 10 (Very Poor) and the higher score indicates severe disease activity. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as the post-dose visit value minus Baseline value.
| Scores on a scale | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Week 8; n=66, 132, 44 | -0.96 ± 2.751 | -1.06 ± 2.141 | -0.91 ± 2.848 |
| Week 12; n=66, 133, 44 | -0.69 ± 2.237 | -1.07 ± 2.290 | -1.57 ± 2.756 |
| Week 26; n=61, 115, 40 | -0.95 ± 2.765 | -1.50 ± 2.596 | -1.57 ± 2.450 |
| Week 40; n=63, 123, 43 | -1.77 ± 2.624 | -1.60 ± 2.809 | -1.67 ± 2.962 |
| Week 52; n=64, 120, 41 | -1.74 ± 2.752 | -1.82 ± 2.631 | -1.84 ± 3.228 |
| Week 64; n=62, 117, 36 | -1.41 ± 2.985 | -1.96 ± 2.595 | -1.96 ± 3.034 |
| Week 72; n=59, 107, 33 | -1.46 ± 3.209 | -1.81 ± 2.609 | -1.43 ± 3.487 |
| Week 104; n=55, 111, 36 | -1.61 ± 2.589 | -2.00 ± 2.739 | -1.98 ± 2.895 |
LupusQoL is a SLE-specific health related qualify of life (HRQOL) instrument with 34 questions across 8 domains:Physical health(8 items),Pain(3 items),Planning(3 items),Intimate relationship(2 items),Burden to others(3 items),Emotional health(6 items),Body image(5 items),Fatigue(4 items). Questions were related to participants experience in prior 4 weeks.A 5-point Likert response format was used, ranging from 0(all of the time) to 4(never) for each question. Individual domain scores were reported which were calculated by taking sum of responses to all items within each domain. Individual domain scores range:Physical health(0-32),Pain(0-12),Planning(0-12),Intimate relationship(0-8),Burden to others(0-12),Emotional health(0-24),Body image(0-20),Fatigue(0-16). Higher score indicates better HRQOL. Baseline value was latest pre-dose assessment with a non-missing value including those from unscheduled visits. Change from Baseline was defined as post-dose visit value minus Baseline value.
| Scores on a scale | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Physical health; Week 8; n=66, 132, 44 | 3.0 ± 15.20 | 6.0 ± 15.08 | 6.3 ± 18.79 |
| Physical health; Week 12; n=66, 133, 44 | 3.5 ± 16.60 | 5.8 ± 17.15 | 6.4 ± 20.06 |
| Physical health; Week 26; n=61, 115, 40 | 3.3 ± 18.74 | 10.5 ± 17.27 | 11.6 ± 19.19 |
| Physical health; Week 40; n=63, 122, 43 | 8.5 ± 19.53 | 9.5 ± 19.29 | 8.2 ± 19.46 |
| Physical health; Week 52; n=64, 120, 41 | 8.1 ± 19.90 | 10.0 ± 20.16 | 11.6 ± 19.53 |
| Physical health; Week 64; n=62, 117, 36 | 5.8 ± 18.66 | 10.2 ± 18.60 | 9.5 ± 21.74 |
| Physical health; Week 72; n=59, 107, 33 | 7.0 ± 21.13 | 9.1 ± 18.84 | 8.5 ± 22.59 |
| Physical health; Week 104; n=55, 111, 36 | 6.2 ± 20.19 | 10.6 ± 19.96 | 7.2 ± 23.33 |
| Pain; Week 8; n=66, 132, 44 | 5.8 ± 19.67 | 11.4 ± 18.55 | 10.4 ± 21.87 |
| Pain; Week 12; n=66, 133, 44 | 7.5 ± 19.78 | 13.0 ± 20.81 | 6.1 ± 28.44 |
| Pain; Week 26; n=61, 115, 40 | 7.0 ± 22.42 | 17.2 ± 21.54 | 13.1 ± 22.79 |
| Pain; Week 40; n=63, 122, 43 | 12.3 ± 23.18 | 18.0 ± 22.70 | 12.6 ± 29.17 |
| Pain; Week 52; n=64, 120, 41 | 13.9 ± 24.26 | 17.6 ± 23.62 | 15.7 ± 27.34 |
| Pain; Week 64; n=62, 117, 36 | 10.2 ± 21.89 | 17.4 ± 23.59 | 13.2 ± 26.90 |
| Pain; Week 72; n=59, 107, 33 | 13.1 ± 24.91 | 17.0 ± 22.66 | 11.9 ± 29.02 |
| Pain; Week 104; n=55, 111, 36 | 13.8 ± 25.82 | 19.0 ± 22.59 | 12.5 ± 27.92 |
| Planning; Week 8; n=66, 132, 44 | 3.4 ± 19.77 | 8.0 ± 18.21 | 10.0 ± 27.88 |
| Planning; Week 12; n=66, 133, 44 | 4.5 ± 23.03 | 7.6 ± 20.15 | 7.8 ± 27.81 |
| Planning; Week 26; n=61, 115, 40 | 3.4 ± 25.20 | 9.9 ± 21.28 | 12.1 ± 27.86 |
| Planning; Week 40; n=63, 122, 43 | 11.6 ± 29.08 | 12.2 ± 22.30 | 10.7 ± 26.62 |
| Planning; Week 52; n=64, 120, 41 | 11.6 ± 28.66 | 12.6 ± 23.89 | 14.0 ± 28.35 |
| Planning; Week 64; n=62, 117, 36 | 7.8 ± 24.42 | 14.5 ± 23.65 | 7.2 ± 30.55 |
| Planning; Week 72; n=59, 107, 33 | 9.2 ± 30.78 | 11.4 ± 20.97 | 6.6 ± 31.02 |
| Planning; Week 104; n=55, 111, 36 | 12.1 ± 30.76 | 14.2 ± 20.77 | 8.8 ± 34.96 |
| Intimate relationship; Week 8; n=51, 110, 36 | -1.2 ± 21.83 | 5.2 ± 20.63 | 7.6 ± 19.66 |
| Intimate relationship; Week 12; n=52, 106, 36 | -2.6 ± 25.16 | 4.6 ± 23.42 | 7.6 ± 27.10 |
| Intimate relationship; Week 26; n=48, 86, 30 | -1.3 ± 29.20 | 8.9 ± 24.32 | 14.2 ± 28.38 |
| Intimate relationship; Week 40; n=50, 94, 30 | 4.3 ± 28.75 | 7.7 ± 25.01 | 15.8 ± 30.43 |
| Intimate relationship; Week 52; n=51, 91, 30 | 4.7 ± 29.36 | 6.6 ± 22.54 | 15.8 ± 30.78 |
| Intimate relationship; Week 64; n=47, 90, 25 | -4.5 ± 28.00 | 11.0 ± 25.41 | 12.5 ± 29.76 |
| Intimate relationship; Week 72; n=42, 83, 21 | 0.0 ± 31.60 | 8.6 ± 23.82 | 5.4 ± 39.44 |
| Intimate relationship; Week 104; n=40, 85,27 | -0.3 ± 23.93 | 11.2 ± 25.59 | 4.6 ± 35.21 |
| Burden to others; Week 8; n=66, 132, 44 | 7.3 ± 22.95 | 6.8 ± 20.56 | 10.6 ± 23.46 |
| Burden to others; Week 12; n=66, 133, 44 | 11.4 ± 27.91 | 8.4 ± 23.65 | 6.4 ± 29.90 |
| Burden to others; Week 26; n=61, 115, 40 | 8.7 ± 26.68 | 10.5 ± 27.42 | 7.5 ± 27.66 |
| Burden to others; Week 40; n=63, 122, 43 | 13.9 ± 27.23 | 12.6 ± 26.94 | 12.0 ± 27.66 |
| Burden to others; Week 52; n=64, 120, 41 | 16.5 ± 29.15 | 14.9 ± 27.03 | 15.0 ± 33.40 |
| Burden to others; Week 64; n=62, 117, 36 | 14.4 ± 28.83 | 17.0 ± 26.67 | 12.3 ± 28.21 |
| Burden to others; Week 72; n=59, 107, 33 | 17.1 ± 28.68 | 14.4 ± 28.77 | 11.1 ± 27.85 |
| Burden to others; Week 104; n=55, 111, 36 | 18.9 ± 25.93 | 15.0 ± 29.25 | 12.7 ± 33.42 |
| Emotional health; Week 8; n=66, 132, 44 | 5.2 ± 18.33 | 6.4 ± 16.87 | 11.6 ± 20.55 |
| Emotional health; Week 12; n=66, 133, 44 | 8.1 ± 17.32 | 4.5 ± 19.67 | 9.1 ± 23.87 |
| Emotional health; Week 26; n=61,115, 40 | 7.7 ± 19.84 | 6.7 ± 17.35 | 10.1 ± 18.12 |
| Emotional health; Week 40; n=63, 122, 43 | 9.7 ± 21.44 | 6.7 ± 20.85 | 9.4 ± 22.20 |
| Emotional health; Week 52; n=64, 120, 41 | 10.2 ± 21.48 | 7.8 ± 20.63 | 11.4 ± 21.99 |
| Emotional health; Week 64; n=62, 117, 36 | 8.1 ± 20.75 | 9.3 ± 20.73 | 8.1 ± 22.11 |
| Emotional health; Week 72; n=59, 107, 33 | 8.8 ± 21.39 | 6.2 ± 19.05 | 6.6 ± 21.80 |
| Emotional health; Week 104; n=55, 111, 36 | 6.8 ± 20.20 | 9.3 ± 19.67 | 10.5 ± 23.00 |
| Body image; Week 8; n=60, 114, 37 | 5.7 ± 19.57 | 8.9 ± 19.26 | 5.7 ± 25.05 |
| Body image; Week 12; n=58, 118, 39 | 1.9 ± 23.23 | 10.1 ± 20.73 | 5.9 ± 26.89 |
| Body image; Week 26; n=56, 96, 33 | 5.8 ± 20.62 | 9.0 ± 25.03 | 5.7 ± 23.07 |
| Body image; Week 40; n=54, 103, 35 | 8.9 ± 25.42 | 8.2 ± 24.82 | 5.1 ± 22.07 |
| Body image; Week 52; n=55, 101, 33 | 7.9 ± 25.77 | 9.1 ± 24.07 | 10.3 ± 25.24 |
| Body image; Week 64; n=52, 98, 27 | 6.0 ± 22.51 | 11.3 ± 23.08 | 7.7 ± 23.98 |
| Body image; Week 72; n=44, 93, 25 | 7.8 ± 26.74 | 8.7 ± 24.91 | 2.5 ± 29.28 |
| Body image; Week 104; n=48, 94, 28 | 4.4 ± 26.62 | 11.4 ± 25.65 | 3.5 ± 27.40 |
| Fatigue; Week 8; n=66,132, 44 | 9.8 ± 17.02 | 9.2 ± 18.40 | 8.5 ± 24.30 |
| Fatigue; Week 12; n=66, 133, 44 | 8.2 ± 18.48 | 7.0 ± 17.96 | 10.4 ± 28.11 |
| Fatigue; Week 26; n=61, 115, 40 | 8.6 ± 20.23 | 11.4 ± 20.12 | 11.9 ± 20.21 |
| Fatigue; Week 40; n=63, 122, 43 | 11.9 ± 22.33 | 10.3 ± 22.41 | 11.3 ± 24.75 |
| Fatigue; Week 52; n=64, 120, 41 | 14.2 ± 21.17 | 12.0 ± 20.95 | 16.6 ± 25.30 |
| Fatigue; Week 64; n=62, 117, 36 | 10.5 ± 21.94 | 14.0 ± 20.35 | 10.8 ± 25.21 |
| Fatigue; Week 72; n=59, 107, 33 | 12.1 ± 22.74 | 13.1 ± 18.31 | 11.6 ± 25.87 |
| Fatigue; Week 104; n=55, 111, 36 | 9.4 ± 20.41 | 14.3 ± 20.18 | 9.7 ± 24.25 |
The FACIT-Fatigue scale was a 13-item questionnaire completed by the participant, which provides a measure of fatigue/quality of life, with a 7-day recall period. The participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The higher score for the questions, the greater the fatigue. The total score was the sum of the responses from all questions (inverted for reversed items) multiplied by 13, then divided by the number of questions answered, ranging from 0 (worse fatigue) to 52 (no fatigue) where a higher score indicates an improvement in the participant's health status and decrease in the score indicates worse fatigue/quality of life. Baseline value was the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was defined as the post-dose visit value minus Baseline value.
| Scores on a scale | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Week 8; n=66, 132, 44 | 4.2 ± 9.84 | 4.6 ± 8.84 | 4.8 ± 8.25 |
| Week 12; n=66, 133, 44 | 4.7 ± 9.50 | 4.0 ± 9.86 | 3.8 ± 10.94 |
| Week 26; n=61, 115, 40 | 3.1 ± 10.08 | 5.4 ± 9.17 | 4.1 ± 8.54 |
| Week 40; n=63, 122, 43 | 6.0 ± 10.18 | 5.2 ± 10.80 | 5.2 ± 10.14 |
| Week 52; n=64, 120, 41 | 6.5 ± 10.12 | 6.1 ± 10.84 | 5.1 ± 10.51 |
| Week 64;n=62, 117, 36 | 4.9 ± 10.61 | 6.2 ± 9.72 | 4.6 ± 10.32 |
| Week 72; n=59, 107, 33 | 5.6 ± 10.21 | 5.2 ± 10.31 | 2.9 ± 12.75 |
| Week 104; n=55, 111, 36 | 5.7 ± 9.07 | 7.1 ± 11.50 | 3.1 ± 10.30 |
The FACIT-Fatigue scale was a 13-item questionnaire completed by the participant, which provides a measure of fatigue/quality of life, with a 7-day recall period. The participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions, the greater the fatigue. The total score was the sum of the responses (inverted for reversed items) multiplied by 13, then divided by the number of questions answered, ranging from 0 (worse fatigue) to 52 (no fatigue) where a higher score indicates an improvement in the participant's health status and decrease in the score indicates worse fatigue/quality of life. A participant was considered to had an improvement exceeding the minimal clinically important difference if they had \>=4 points improvement in their FACIT-Fatigue Scale score from Baseline. Percentage of participants with improvement in FACIT-Fatigue scale score exceeding the MCID (\>=4 points) were summarized.
| Percentage of participants | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Week 8; n=66, 132, 44 | 47.0 (34.9 to 59.0) | 51.5 (43.0 to 60.0) | 59.1 (44.6 to 73.6) |
| Week 12; n=66, 133, 44 | 56.1 (44.1 to 68.0) | 50.4 (41.9 to 58.9) | 52.3 (37.5 to 67.0) |
| Week 26; n=61, 115, 40 | 47.5 (35.0 to 60.1) | 56.5 (47.5 to 65.6) | 45.0 (29.6 to 60.4) |
| Week 40; n=63, 122, 43 | 54.0 (41.7 to 66.3) | 54.1 (45.3 to 62.9) | 53.5 (38.6 to 68.4) |
| Week 52; n=64, 120, 41 | 60.9 (49.0 to 72.9) | 58.3 (49.5 to 67.2) | 56.1 (40.9 to 71.3) |
| Week 64; n=62, 117, 36 | 51.6 (39.2 to 64.1) | 59.8 (50.9 to 68.7) | 52.8 (36.5 to 69.1) |
| Week 72; n=59, 107, 33 | 57.6 (45.0 to 70.2) | 57.0 (47.6 to 66.4) | 42.4 (25.6 to 59.3) |
| Week 104; n=55, 111, 36 | 56.4 (43.3 to 69.5) | 62.2 (53.1 to 71.2) | 44.4 (28.2 to 60.7) |
Collected over All-cause mortality, serious adverse events (SAEs) and non-SAEs were collected up to Week 111 (including 8 weeks of safety follow-up).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Belimumab + Placebo | 1/72 (1.4%) | 10/72 (13.9%) | 48/72 (66.7%) |
| Belimumab + Rituximab | 2/144 (1.4%) | 32/144 (22.2%) | 109/144 (75.7%) |
| Belimumab + Standard Therapy | 0/76 (0%) | 15/76 (19.7%) | 53/76 (69.7%) |
| Event | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| Chest painGeneral disorders | 1/72 | 1/144 | 0/76 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/72 | 1/144 | 0/76 |
| Urinary tract infectionInfections and infestations | 0/72 | 2/144 | 0/76 |
| VasculitisVascular disorders | 0/72 | 2/144 | 0/76 |
| AngioedemaSkin and subcutaneous tissue disorders | 1/72 | 0/144 | 0/76 |
| Arthritis bacterialInfections and infestations | 1/72 | 0/144 | 0/76 |
| Cardiac failure congestiveCardiac disorders | 1/72 | 0/144 | 0/76 |
| CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/72 | 0/144 | 0/76 |
| GastritisGastrointestinal disorders | 1/72 | 0/144 | 0/76 |
| Jugular vein thrombosisVascular disorders | 1/72 | 0/144 | 0/76 |
| Event | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy |
|---|---|---|---|
| HeadacheNervous system disorders | 13/72 | 30/144 | 8/76 |
| Urinary tract infectionInfections and infestations | 12/72 | 23/144 | 10/76 |
| NasopharyngitisInfections and infestations | 9/72 | 23/144 | 11/76 |
| Upper respiratory tract infectionInfections and infestations | 5/72 | 22/144 | 9/76 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/72 | 12/144 | 10/76 |
| NauseaGastrointestinal disorders | 2/72 | 18/144 | 2/76 |
| InfluenzaInfections and infestations | 9/72 | 4/144 | 4/76 |
| BronchitisInfections and infestations | 6/72 | 10/144 | 7/76 |
| DiarrhoeaGastrointestinal disorders | 6/72 | 6/144 | 5/76 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 6/72 | 3/144 | 2/76 |
Baseline characteristics were presented for Intent-to-Treat Population.
| Age, Continuous(Years) | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy | Total |
|---|---|---|---|---|
| Mean | 40.6 ± 12.58 | 40.1 ± 11.45 | 41.0 ± 12.75 | 40.5 ± 12.04 |
| Sex: Female, Male(Participants) | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy | Total |
|---|---|---|---|---|
| Female | 66 | 129 | 73 | 268 |
| Male | 6 | 15 | 3 | 24 |
| Race/Ethnicity, Customized(Participants) | Belimumab + Placebo | Belimumab + Rituximab | Belimumab + Standard Therapy | Total |
|---|---|---|---|---|
| White -Arabic/North African Heritage | 0 | 1 | 1 | 2 |
| White-White/Caucasian/European Heritage | 39 | 100 | 47 | 186 |
| Asian - Central/South Asian Heritage | 0 | 1 | 1 | 2 |
| Asian - East Asian Heritage | 7 | 14 | 10 | 31 |
| Asian - South East Asian Heritage | 3 | 2 | 1 | 6 |
| African American/African Heritage | 21 | 22 | 13 | 56 |
| American Indian or Alaskan Native | 1 | 3 | 3 | 7 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data (IPD) and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from Mar 2018 to primary completion in May 2020, 26 months.
Results were first posted in Apr 2022, 1 year 10 months after primary completion. A results delay was requested in Dec 2020.
Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 26 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab
Lupus Erythematosus, Systemic →